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CD23 (FcεRII), a C-type lectin type II membrane glycoprotein, plays an 
important role in IgE homeostasis and development of allergic inflammation. I 
showed that CD23 was constitutively expressed in the established or primary human 
airway epithelial cells and its expression was significantly up-regulated by IL-4 
stimulation. In a transcytosis assay, human IgE or IgE derived immune complex was 
transported and enhanced by IL-4 stimulation across a polarized Calu-3 monolayer. A 
CD23 specific antibody or soluble CD23 significantly reduced the transcytosis, 
suggesting a specific receptor-mediated transport by CD23. Transcytosis of both IgE 
and the immune complex was further verified in primary human airway epithelial cell 
monolayers. Furthermore, the transcytosed antigen-IgE complexes were competent in 
inducing degranulation of the cultured human mast cells. This study implies CD23-
mediated IgE transcytosis in human airway epithelial cells may play a critic l ole in 
  
initiating and contributing to the perpetuation of airway allergic inflammation.  
To verify the above results in a mouse model, CD23 expression was detected 
in epithelial cells lining mouse airway and enhanced by IL-4 exposure as wll as in 
ovalbumin (OVA) sensitized mouse. I showed that CD23 transported IgE and OVA-
IgE derived immune complex across airway epithelial cells in wild-type, but not 
CD23 knockout (KO), mice. The chimeric CD23KO mice repopulated with wild-type 
myeloid cells, sensitized and challenged with OVA showed significant reduction in 
siglec-F+ cells, eosinophils, macrophages and IL-4 in bronchoalveolar lavage fluid 
recovered 24 hours later compared to the wild-type mice.  
Our finding of CD23-mediated IgE transport in airway epithelial cells suggest 
a possibility of CD23 transporting an IgE Fc-fused protein for immunotherapy. 
CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) which competitively binds CD80 and 
CD86 expressed on antigen presenting cells and inhibits CD28 mediated co-
stimulation of T cell activation. A CTLA4-Fc (IgE) fusion protein produced in 
Chinese hamster ovary cells was intranasally administrated into mouse airway fo  
assessing its specific transport by CD23. The effect of this fusion protein on the
development of allergic inflammation is being fully investigated in wild-type, CD23-
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CHAPTER 1: INTRODUCTION 
OVERVIEW 
Immunoglobulin E and human diseases 
In the developed world, there is an increased incidence of Immunoglobulin E 
(IgE) mediated diseases like allergy. In February 1968, the name Immunoglobulin E was 
officially given to the final class of human antibody in the World Health Organization 
Immunoglobulin Reference Laboratory meeting held in Lucerne, Switzerland (1). 
Initially, IgE was found to have effector functions against invading parasites and in the 
controlling of the parasitic diseases. Later on, the beneficial effect of the IgE was 
overridden by the harmful effects in the body by developing various IgE mediated 
allergic diseases. The body responds to the exogenous antigen called allergen nd 
develops allergen specific IgE, leading to the exacerbation of the allergic diseases by 
releasing various allergic mediators. IgE mediated allergic disease  include allergic 
rhinitis, asthma, food allergy, systemic anaphylaxis, urticaria and atopic dermatitis or 
eczema. Asthma is a chronic lung disease that inflames and narrows the airways. It 
affects people of all ages, but it occurs most frequently in childhood. The exact cause of 
asthma remains elusive. A combination of factors, such as family genetics, r spiratory 
infections, and certain environmental exposures are involved in developing asthma. 
Ongoing airway inflammation results in abnormal structural changes in the airway due to 
the epithelial desquamation/denudation and repair processes (2). Food allergy is 
characterized by the abnormal immune response to the harmless food substance in certain 
individuals, resulting in production of food allergen specific IgE and characterized by 




difficulty and hives or eczema. In most cases, avoiding the food allergen may by the est 
way to prevent the food allergy.  However, it is very difficult to find good nutritious food 
to avoid infant food allergy. The worst case of the allergic diseases can lead to 
anaphylaxis and if left untreated, they can result in the death due to anaphylactic sho k by 
arresting breathing and blood circulation.  
 
After the first time exposure to an allergen, allergen specific IgE can be developed 
against that particular allergen. The antigen presenting cells (APCs) can take up and 
process this allergen and migrate to the draining lymph node where allrgens are 
presented to the naive CD4+ T cells.  These T cells will differentiate into helper T (Th2) 
cells which secrete large quantities of cytokines IL-4 and IL-13. The B c lls present in 
the lymph node also recognize, take up and process the allergens. Under a Th2 
environment, B cells can class switch to produce IgE against the allergen. Allergen 
specific IgE binds to the high affinity receptor for IgE, FcεRI which is typically 
expressed on the mast cells, eosinophils, and basophils (1). This process is called
sensitization. During a subsequent exposure, the same allergen will cross-link IgE/FcεRI 
resulting in the release of various inflammatory mediators, a phenomenon called 
degranulation. Degranulation occurs within the minutes of the allergen exposure. Mast 
cells and basophils release various cytokines, chemokines, histamine, leukotrienes and 
prostaglandins (3). These mediators  subsequesntly bind to their specific receptors 
expressed on the smooth muscle cells, epithelial cells, and blood vessels, leading to 
muscle contraction, increased mucus production and vascular permeability. In the latter 




cytokines and chemokines that recruit eosinophils and Th2 cells (3). The long-lasting 
effects of these mediators lead to the remodeling of airway that is responsible for various 
allergic manifestations and symptoms in asthmatic patients.  
 
Discovery of IgE        
 In 1921, Prausnitz and Kustner originally showed that transfer of serum from an 
allergic patient to a non-allergic patient resulted in sensitization of the non-allergic 
patient and they named the molecule responsible for this activity as reagin(4).   This test 
was also known as the Prausnitz-Kustner (PK) test. In 1967, two groups independently 
identified the protein present in the reaginic preparation. Ishizakas prepared the γΕ 
antisera, and with the help of radioimmunodiffusion assay showed γΕ precipitin bands 
and purified the protein present in the reagin preparation while, Stanworth et al. 
discovered a myeloma protein that inhibits the PK reaction (5-8).  In 1968, the World 
Health Organization Immunoglobulin Reference Laboratory meeting named the final and 
fifth class of human immunoglobulin as IgE.  
 
Structure of IgE 
 Like other immunoglobulin molecules, IgE consists of two identical heavy and 
light chains as illustrated in the Figure 1.1. The heavy chain of IgE consists of one 
variable heavy (VH) domain and four constant epsilon domains (Cε1−Cε4). The Cε3 and 
Cε4 are homologous in structure and sequence to the heavy gamma chain domain 
Cγ2 and Cγ3 in IgG. Interestingly, the Cε2 domain corresponds the hinge region of the 




including the disulphide-linked Cε2 domain reveals that Cε2 domain is much closer to 
the Cε3 domain with extensive contact with Cε3 and Cε4 domains, which leads to 
asymmetrically bent conformation in IgE (11).  
 
RECEPTORS FOR IGE 
There are two kinds of membrane receptors for IgE, high affinity receptor for IgE 
(FcεRI) and low affinity receptor for IgE (FcεRII or CD23).  Soluble receptors for IgE 
includes soluble FcεRI (sFcεRI), soluble CD23 (sCD23) and galectin-3 (1, 12). Only in 
the mouse, FcγRIV, homologous to the FcγRIIIA in humans is capable of binding IgE 
with a low affinity; but, hFcγRIIIA does not bind to human IgE. Mouse FcγRIV is 
expressed in the lung macrophages and can also binds to IgG with intermediate affinity. 
However; it will be readily displaced by IgE immune complexes in the lung and plays a 
regulatory role in the lung inflammation (13).  
 
Structure, expression and function of FcεRI. 
FcεRI expressed on the mast cells and basophils is responsible for the 
degranulation and the release of inflammatory mediators responsible for the development 
of allergy. FcεRI is expressed as a tetrameric complex made of an alpha subunit 
responsible for binding to IgE, a beta subunit and two gamma subunit linked by a 
disulphide bond (FcεRIαβγ2) as shown in the Figure 1.2 (1, 14-18). While the alpha 
subunit binds to the IgE, FcεRI signals through immunoreceptor tyrosine based activation 
motif (ITAM) carried in beta and gamma subunits. These two subunits act synergistically 




(FcεRIαγ2) that lacks beta subunit in mast cells, basophils and antigen presenting cells, 
monocytes, smooth muscle cells, eosinophils, neutrophils and platelets. In rodents, the 
trimeric form of FcεRI (FcεRIαγ2) is not detected so far (1, 14-18).   
Among all the Fc receptors, FcεRI has the highest affinity for IgE with Ka ≈ 10
10 
M-1 (1). FcεRI is involved in the development of allergy. Allergen specific IgE binds to 
the FcεRI expressed on the mast cells and basophils and the cross linking of the IgE- 
FcεRI complexes by the allergen specific IgE leads to the degranulation, with the release 
of various inflammatory mediators,  like histamine, prostaglandins, serotonin, 
leukotrienes (3, 19-21) and various cytokines, such as IL-4, IL-3, IL-5, IL-6, IL-13, IFN-
γ and granulocyte macrophage colony-stimulating factors (3, 22-24). The release of 
inflammatory mediators is the hallmark for the development of allergy or immediate type 
1 hypersensitivity (1). FcεRI expressed on the APC also takes part in the antigen uptake, 
processing and presentation to T cells and involved in Th2-dependent allergic 
inflammation (25- 27).  
 
SOLUBLE RECEPTORS FOR IGE 
Soluble FcεRI (sFcεRI) 
Soluble form of FcεRI (sFcεRI) is found in the human serum. This 40 kDa 
molecule of sFcεRI is generated from the alpha chain of FcεRI and it can bind to the 
human IgE. Since the alpha chain of FcεRI binds to IgE with very high affinity, it is 
expected that sFcεRI also binds to IgE with a similarily high affinity (28). Recombinant 
sFcεRI has been shown to prevent anaphylactic shock and allergic disease in a 














Figure 1.1 Comparison of structure of IgE and IgG. Structural domain organization of 
human IgE and IgG1 showing intra and inter disulphide linkage bonds and site for N-














mechanism is that sFcεRI can bind to free IgE and IgE immune complexes thereby 
reducing the availability of these IgE immune complexes for interacting w th the FcεRI 
on the surface of basophils and mast cells (12). 
 
 Galectin-3 
  Galectin-3 previously known as ε−binding protein is a 30 kDa secretory protein 
and belongs to β-galactose containing oligosaccharide lectin protein (32). It has the 
ability to bind both IgE and FcεRI and this can activate the FcεRI bound with or without 
IgE on the mast cells or basophils (33-35). Galaetin-3 consists of a carbohydrate-
recognition domain (CDR) with proline and glycine rich repeats at amino terminal 
through which it can form a pentameric structure similar to IgM as shown in theFigure 
1.3 (36). Differentially glycosylated IgE has exhibited distinct binding properties to 
galectin-3 (37, 38). 
 
Galectin-3 is found on the surface of variety of cells like neutrophils, mast cells, 
eosinophils, keratinocytes, monocytes, macrophages, T cells and bronchial epithelium of 
airways (39-46). Murine CD4+ and CD8+ T cells but not the resting T cells express 
galectin-3 under the influence of IL-2, IL-4, and IL-7 (44).  Galectin-3 expressed in T 
cells contributes to the growth and survival of T cells (45). Galectin-3 is also found t be 
expressed in the bronchial epithelium of the small airways of patients with chroni  
obstructive pulmonary disease (COPD) (46).  In addition, Galectin-3 plays an important 
role in the binding to the IgE on the mast cells and activates the mast cells through c ss 







Figure 1.2 Structure of high affinity receptor for IgE, FcεRI and low affinity 










cells (33). Galectin-3 mediated IgE dependent allergic disease activation and cytotoxicity 
have also been found in human neutrophils and eosinophils (39, 41). 
 
LOW AFFINITY RECEPTOR FOR IGE, CD23 OR FcεRII  
Discovery of CD23 
In the year 1975, Lawrence et al. first showed the presence of a receptor for IgE
on the human lymphocytes (47). In 1976, IgE myeloma protein was found to bind 
cultured lymphoblastoid cell lines in a species specific manner (48).  IgE bound to the 
receptor expressed on lymphocytes with a relatively low affinity (Ka ≈ 10
6 -107 M-1) 
compared to the high affinity receptor FcεRI expressed on the mast cells, hence named as 
low affinity receptor for IgE or FcεRII. Later two groups independently identified the 
CD23 molecule. First in 1985, Epstein Barr virus (EBV) activates a cell surface m rker in 
human B cells which is named as BLAST-2 or EBVCS (49). Another group in 1987 
showed that EBV infection induced the expression of activation marker CD23 in B cells 
(50). In 1987, two individual groups with the help of monoclonal antibody (mAb) 
showed that CD23 was expressed on human lymphocytes and identified that BLAST-2, 
EBVCS and CD23 are the same (51,52). Cloning of the human CD23 cDNA was later 
achieved by three different groups. They showed that CD23 is a type II transmembran  
protein consisting of 321 amino acids with its N-terminus in the cytoplasm and C-
terminus on the cell surface. The amino acid sequence of CD23 shows a marked 
homology with animal lectin and closely resembling human, rat and chicken 
asialoglycoprotein receptors (53-55). Unlike other immunoglobulin (Ig) receptors, CD23 







Figure 1.3 Membrane associated receptors for IgE and its soluble forms. FcεRI is 
expressed as tetrameric FcεRIαβγ2 or FcεRIαγ2 and its soluble form sFcεRI was 
generated from the alpha chain of FcεRI. Low affinity receptor for IgE, (FcεRI or CD23) 
expressed as oligomeric or trimeric form on the cell surface and different molecular 
weight of soluble CD23 was generated by intracellular or extracellular proteolytic 
cleavage of full length membrane expressed CD23. Galectin-3 is a secretory protein with 










CD23 is dependent on calcium, and it recognizes a Cε3 domain of IgE independent of the 
IgE oligosaccharides (56, 57).  Mouse CD23 is also a type II transmembrane protein with 
331 amino acids and two N-linked glycosylation sites sharing 57% amino acid sequence 
identity with human CD23 (58,59).  
 
Structure of CD23 
  Different from all other immunoglobulin receptors, CD23 belongs to a C-type 
lectin family consisting of three lectin head domains in the carboxy terminal region 
followed by a triple α−helical coiled-coil stalk region, transmembrane and short 
cytoplasmic tail domain as illustrated in the Figure 1.4 (1). The stalk region of the CD23 
has a highly similar sequence to tropomyosin that has a α−helical coiled coil structure 
with heptad repeats (60).  Through chemical cross linking studies, it was found that CD23 
stalk region containing the α−helical coiled coil stalk region enable the oligomerization 
of CD23 to form trimer. It was also showed that CD23 can bind IgE with both high and 
low affinity (61). Development of mAb B3B4 against murine CD23 showed that two 
lectin head domains of CD23 bind to one IgE cooperatively (62). CD23, the low affinity 
receptor for IgE, is later considered as a misnomer since CD23 in the monomeric stat  
binds IgE with low affinity (Ka ≈ 10
6 -107 M-1), while the trimeric form of CD23 binds 
IgE with high affinity (Ka ≈ 10
8 -109 M-1) (1, 63,64). Using the mAb directed against the 
stalk region of murine CD23, it was demonstrated that CD23 is preassociated as a trimer
on the cell surface (65). CD23 trimerization (65,66)  brings their lectin domains close to 
each other leading to cooperative and high affinity binding of single IgE molecule (63,64, 




human CD23 contains additional C-terminal tail (1). Nuclear magnetic resonance 
spectroscopy of CD23 revealed the three dimensional structure of the C-type lecin 
domain. CD23 binds to both the ligands IgE and CD23 simultaneously and does not 
require calcium for its interaction (64). 
 
Expression and regulation of CD23 
Human CD23 is expressed in variety of cells such as B cells, monocytes, 
eosinophils, platelets (68-71), Langerhans cells and intestinal epithelial cel s (72-75). 
CD23 exists as two isoforms, CD23a and CD23b; they are arised from the alternative 
RNA splicing with different transcription initiation sites and differing only in the N-
terminal cytoplasmic region by 6-7 amino acids (76). In humans, the isoform CD23a is 
expressed only in the B lymphocytes while CD23b is expressed in variety of cells like 
monocytes, eosinophils and langerhans cells (77). In mice, CD23 is expressed in B cells, 
follicular dendritic cells, intestinal epithelial cells (58, 78, 79, 80, 81).  Regarding the 
isoforms, murine CD23a is expressed in the B cells and follicular dendritic cells and 
CD23b is expressed in follicular dendritic cells and intestinal epithelial cels (77). FcεRII 
(CD23) is expressed in the B cells based on the differentiation stage, for exampl, human 
bone marrow-derived B cells with surface IgM and IgD do not express CD23 whereas 
circulating B cells with surface IgM and IgD express CD23 (82), and the murine B cells 
also express CD23 (83). Majority of the CD27+ memory B cells do not express CD23, 
however a small subset of B cells co- express both CD23 and CD27 (84). Mouse 
intestinal epithelial cells also express CD23. Mouse CD23 is also expressed as CD23a 

















Figure 1.4 Structure of CD23: a. Schematic presentation of membrane bound CD23 
showing extracellular trimeric coiled-coil stalk region, head domain, C-terminal tail and 
site for N-linked glycosylation, transmembrane domain and N terminal region. b. Three
dimensional structure of one of the head domain showing the binding sites for IgE, CD21 









documented in the intestinal epithelial cells (78, 79).  
   CD23 expression is well known to be regulated by cytokines (80, 81, 85-98) and 
IgE ligands (99, 100). Th2 cytokines like IL-4 and IL-13 increases CD23 expression at 
both the mRNA and protein levels (94-98). In the human B cells, IL-13 alone can induce 
the CD23 expression and no synergistic enhancement is observed with IL-4 (98). In 
normal human peripheral blood T (PBT) cells, IL-7 treatment increased the 
intracytoplasmic level of the CD23 (88). In human B lymphocytes, TNF-α had an 
antagonist effect on the IL-4 induced CD23 production and its inhibitory effect is greater 
than the effect of interferons (IFN) (89). The cytokines IFN-α and IFN-γ have been 
shown to both enhance and decrease the expression of CD23 (90-94). While IFN-α 
enhanced the expression of CD23 in U937 cells (92), IFN-α had an opposite effect of 
suppressing the CD23 expression on lymphocytes in Peyer’s patches (93). Likewise, 
IFN-γ suppressed IL-4 mediated enhancement of CD23 expression in human B cells and 
monocytes, whereas IFN-γ up-regulated the expression of CD23 in IL-4 treated THP-1 
cells and in human tonsillar mononuclear cells (90, 91, 94). Furthermore, IFN-γ treatment 
alone had either increased the expression of CD23 in the U937 cells or suppressed the 
expression of CD23 in T lymphocytes (92, 95). It remains unclear how these complicated 
regulations occur at molecular level.  In human monocyte and B cell line, IgE and anti-
CD23 mAb increases the surface expression and mRNA of CD23 in a T cell line (99). In 
rodent B cells, IgE increases CD23 expression on the cell surface by preventing its 
degradation but does not affect its synthesis (100). In murine follicular dendritic cells, 
stimulation of CD40 increases mRNA levels of both CD23a and CD23b. Addition of 




treatment enhances only CD23a mRNA expression in follicular dendritic cells (81). 
 
Soluble CD23 (sCD23) 
 Full-length CD23 can be cleaved either extacellularly or intracellularly at 
different locations of the stalk region, consequently generating various sizes of soluble 
CD23. The sizes of these sCD23 are 37 and 28 kDa (62,77,101) in humans and 37, 33, 
25, and 12 kDa in mouse, respectively (77, 102). Importantly, sCD23 retains the globular 
lectin head domain thereby retaining its ability to bind IgE. However, sCD23 interacts 
with IgE with lower affinity (Ka ≈ 10
5 to 106 M-1) compared to the trimeric form of CD23 
(102). It was found that CD23 expressed on the surface of RPMI 8866 B cells was 
cleaved by metalloprotease using various metalloprotease inhibitors (103). Later, a 
disintegrin and metalloproteinase 10 (ADAM10) was found to be responsible for CD23 
cleavage and the releasing of soluble CD23 (104-107). In vivo, ADAM10 is also found 
responsible for cleaving the CD23 by using selective ADAM inhibitor and ADAM 
knockout mice (104).  Mathews et al. in an elegnant experiment described that CD23 in B 
cells is also cleaved intracellularly within the endosome by ADAM10. Thisact on occurs 
in a pH dependent manner and the resultant products are further sorted into the exosomes 
(107). Further experiments are needed to show the physiological relevance of this 
cleavage. The house dust mite D rmatophagoides pteronyssinus protease der p1 also 
cleaves the CD23 into a soluble 17 kDa fragment (108-110).  
 
Binding partners for CD23 




containing proteins (64, 111-116). Recently, through NMR studies, CD23 was found to 
interact with both IgE and CD21 simultaneously and the binding residues for IgE and 
CD21 are distinct. More importantly, this kind of interaction has a functional effect on 
the IgE synthesis and regulation (64). CD21 was found as a ligand for human CD23 by 
using fluorescent liposomes containing full-length CD23 as a probe and it binds to CD21 
on B cells and follicular dendritic cells. This interaction was specifically blocked by 
either anti-CD23 or anti-CD21 mAb (111).  Later the specific site of interaction between 
CD23 on CD21 is mapped, with, extracytoplasmic short consensus repeats (SCR) 5 to 8 
and 1 to 2 on CD21 interacting with human CD23 (112). In addition, CD23 was also 
found to specifically interact with CD11/b/CD18 and CD11/c/CD18 on human 
monocytes. This type of interaction was specifically inhibited by mAb directed against 
CD11/b, CD11/c or CD23. This interaction resulted in significant increase of nitric oxide, 
hydrogen peroxide and proinflammatory cytokines like IL-lβ, IL-8, and TNF-α (113). 
Similarly, murine CD23 also specifically interacts with CD11b, the α chain of β2 integrin 
adhesion molecule CD11b/CD18 complex expressed on monocytes, which results in up-
regulation of IL-6 (114). In human monocytes, sCD23 additionally interacts with 
vitronectin receptor (αvβ3 integrin) and this interaction is further enhanced in the presence 
of vitronectin receptor associated molecule CD47.  The mAbs directed against CD47, 
β3 and vitronectin blocked the release of sCD23-mediated proinflammatory cytokines li e 
TNF-α, IL-12, and IFN-γ (115). Human IgE interacts only with human CD23 and does 
not bind to rodent IgE. The residue Lysine 352 in human IgE is critical  for interaction 
with CD23, its replacement  with  glycine or glutamate results  in a significant reduction 




Functions of CD23 and its soluble form, sCD23 
  
 CD23 has multiple functions: enhancing IgE-specific antigen processing and 
presentation in the form of IgE/antigen complexes (117-124), regulating IgE production 
(63, 64, 125-128), and influencing differentiation, survival and growth of both B- and T-
cells and myeloid precursors (51, 130-135). Both human and mouse intestinal epithelial 
cells expressing CD23 can transport IgE and IgE-antigen immune complexes across the 
intestinal epithelial barrier (140-147). CD23 expressed on mouse B cells allow ntigens 
more efficiently processed in the form of IgE-immune complexes and presented to T cells 
when compared to the antigen alone.  This enhancement of antigen presentation can be 
blocked by a mAb against CD23 (117). Human B lymphocytes expressing CD23 also 
demonstrate an enhanced antigen presentation to the T cells in an IgE dependent man r 
(118).  Furthermore, both in vitro and in vivo assays demonstrate that covalently coupled 
antigen-anti-CD23 conjugates targeted to CD23 enhances antigen presentation to T cells, 
consequently increases the production of antigen specific antibody (119). Similarily, 
CD23 effectively enhances presentation of the major birch pollen allergen, Bet v 1, to Bet 
v 1-specific CD4+ T cells and results in increased production of allergen specific IgE 
antibody. Specific allergen vaccination is successful by controlling CD23 mediated IgE 
dependent antigen presentation to T cells (120,121).  
 
In CD23 knockout mice, IgE-mediated antigen presentation and enhancement of 
antibody responses is blocked in vivo. This experiment defintely demonstrated the role of 
CD23 in IgE-mediated antigen processing and presentation (122). However, enhanced 




possible that CD23 expressed on the nonlymphoid cells like follicular dendritic cells may 
contribute to the suppression of IgE responses (123,124).  
 
 CD23 has been shown to be involved in IgE regulation and synthesis (63, 64, 125-
129), but definite evidence still lacks. Yu et al. shows that thymus dependent antigen 
immunization produced sustained immune response with increased antigen specific IgE 
in CD23 knockout mice, suggesting that CD23 may act as negative feedback for IgE 
regulation (125). On the other hand, CD23 over-expression blocks the IgE production 
both in vivo and in vitro assays (126). Blocking antibody against CD23 also suppresses 
the production of IgE in vitro and in vivo (127,128).  Hibbert et al. proposed a model for 
IgE regulation based on NMR studies of interaction between derCD23/IgE and CD21 as 
shown in the Figure 1.5. Cross-linking of membrane-expressed CD23 and IgE by 
allergen-IgE leads to the down-regulation of IgE synthesis whereas, cross-linking of 
membrane expressed IgE and CD21 by trimeric soluble CD23 causes the up-regulation of 
IgE synthesis (64). In human B cells, soluble CD23 monomers inhibits the IgE synthesis 
whereas, oligomers of soluble CD23 enhanced the IgE synthesis (63). In murine B cells, 
CD23 also regulates the serum IgE levels (129). 
 
 CD23 is shown to be involved in the differentiation of the B cells and prevents 
them from apoptosis (51, 130- 133). Swendeman et al. showed the sCD23 acts as an 
autocrine B cell growth factor for EBV-transformed B cells and normal stimulated B 
cells (131). Later, it was shown that sCD23 prevents the apoptosis of human pre-B cell 




germinal center B cells (132,133) and the maturation and proliferation of early human 
thymocytes and myeloid precursors (134,135).  sCD23 also acts as a proinflammatory 
cytokine and in combination with IL-2 functions  on human peripheral blood 
mononuclear cells (PBMC) to release IFN-γ, TNF-α, IL-1α, IL-1β and IL-6 (136).  
Soluble CD23 was also responsible for inducing IL-8, macrophage inflammatory protein 
(MIP)-1α, and MIP-1β from primary human monocytes (137).  
 
CD23 expression in the intestinal epithelial cells 
 Ramaswamy et al. first showed the evidence of IL-4 dependent IgE uptake and 
transport across the rat intestine in a parasitic infection model (138). Two mAb EBVCS1 
and EBVCS2 specifically detected CD23 in human intestinal epithelial cells and its 
expression level was enhanced in enteropathies (139). Yang et al. showed that CD23 
expressed in intestinal epithelial cells of allergic rats were responsible for the enhanced 
transepithelial HRP transport (140). Using IL-4 and CD23 knockout mice, Yu et al. 
verified that CD23 expressed in the  intestinal epithelial cells of the allergic mice is 
responsible for transport of HRP antigen across the epithelial barrier,which as regulated 
by IL-4 exposure. CD23b and novel CD23b lacking exon 5 or 6 (CD23b∆5/6) has been 
detected in the intestinal epithelial cells of the allergic mice. Interes ingly, CD23b 
isoform is able to transport IgE/allergen complexes whereas CD23b∆5 only transports 
free IgE antibody from apical to basolateral direction (141-143). Human intestinal 
epithelial cells express CD23 and it is capable of transporting human IgE across the 
intestinal epithelium. In addition, human CD23a and CD23b were also expressed in 






Figure 1.5 Model of IgE regulation by CD23.  Cross-linking of membrane expressed 
CD23 and IgE by allergen-IgE immune complex down-regulate the IgE synthesis and 
cross-linking of membrane expressed IgE and CD21 by trimeric sCD23 enhance the IgE















complexes as illustrated in the Figure 1.6 (1, 144,145). Interestingly, CD23 expressed by 
human intestinal epithelial cells can be regulated by p38 MAPK pathway (146). IgE 
immune complexes engaged to human CD23 in the intestinal epithelial cells causes the 
release of IL-8 and CCL20 (147).  
 
TRANSCYTOSIS AND RESPIRATORY EPITHELIAL CELL BIOLOGY  
Transcytosis  
The epithelial monolayer lining the respiratory tract is impervious to 
macromolecule diffusion in the absence of inflammation due to the presence of 
intercellular tight junctions at the apical poles. The tight junctions divide polarized 
epithelial cells into the apical and the basolateral domains (148, 149). These domains 
further form mucosal barriers that allow for the selective exchange of macro olecules 
between the lumen and submucosal tissues. Therefore, soluble macromolecules, like 
immunoglobulins, transported across the mucosal epithelium are mainly mediated by a 
transcellular transport pathway or transcytosis. Specifically, the transcellular pathway 
involves the endocytic uptake of macromolecules, generally by receptor-mediatedand/or 
fluid-phase endocytosis (148, 150), at the apical or basolateral membrane. The molecules 
are then transported through the cell in endocytic vesicles to the opposite membrane 
surface, where they are released into the extracellular space.  
 
ALLERGIC DISEASES IN THE RESPIRATORY TRACT:  
The bronchial epithelium has multifunctional roles (151,152). For many years, 





Figure 1.6 Role of CD23 in food allergy. CD23 expressed in the intestinal epithelium 
binds to IgE in the lamina propria and transport and release into the gut lumen. IgE binds 
to the allergen and form immune complexes in the luminal side. IgE/allergen immune 
complexes are transported back by CD23 and release into the lamina propria. FcεRI 
expressed on mast cells or dendritic cells binds IgE immune complex and cause relea  of 
allergic mediators and local IgE synthesis and secretion. In the chronic stage, in estinal 
luminal barrier is damaged and the allergen can freely move and binds to mast cells and 







secreting mucus, and removing oxious agents by cilia between the internal and external 
milieu of the lungs. More recently, these cells are shown to have a much broad activities 
in communicating with cells of the immune systems, as shown by their ability to produce 
inflammatory mediators and variety of immune molecules (153-155). In particular, 
epithelial cells increase CD23 expression in patients during allergic reactions (156-164). 
CD23 expression has been reported in human bronchial epithelia cells (165), and 
however, its function remains to be defined.  
 
Asthma 
Asthma is a chronic lung disease that inflames and narrows the airways. The exact 
cause of asthma is not known. A combination of factors, such as family genetics, 
respiratory infections, and certain environmental exposures interact to cause asthma to 
develop, most often in the early life. Ongoing airway inflammation results in abnormal 
structural changes in the airway during to the epithelial desquamation/denudatio  and 
repair processes (166). Bronchial inflammation is characterized by infiltration of mast 
cells, basophils, eosinophils, monocytes, and Th2 lymphocytes (166-168). Th2 
lymphocytes play a central role in the pathogenesis of allergic bronchial asthm , since 
each of their characteristic cytokines such as IL-4, IL-5, IL-9 and IL-13 contributes to 
progression of this disease (167,169), including airway eosinophilia, intermittent airway 
obstruction with increased mucus production, and elevated total serum IgE levels by 
production of allergen-specific IgE, and development of airway hyper-responsivene s. 
 




against chicken ovalbumin (OVA) as an allergen. After sensitization and challenge with 
OVA, CD23KO mice developed enhanced allergic airway inflammation with increased 
airway hyperresponsiveness (AHR) when compared to the nonsensitized mice (170, 171). 
Treatment with anti-CD23 mAb but not the anti-CD23 Fab fragment attenuated the 
airway inflammation and AHR, and demonstrated that CD23 negatively regulates the 
airway inflammation. (172). Similarly, after sensitization and challenge with OVA, 
CD23-KO mice produced increased eosinophils in the bronchoalveolar lavage fluid, 
enhanced airway inflammation, and bronchial hyperresponsiveness was observed 
compared to the wild-type mouse control. (173). Sensitization and challenge with OVA 
in CD23 transgenic mice also developed airway inflammation and hyperresponsivenes  
and they showed a negative correlation between AHR and eosinophilia with level of 
CD23 expression in the spleenic T and B cells (171).  
 
Immunoglobulins in mucosal secretions 
 Immunoglobulins (Igs) have been found in a variety of mucosal secretions and 
play first line of defense against mucosally-transmitted pathogens. The major Ig found in 
the mucosal surface of the intestine or upper airway is secretory IgA (sIg ). The 
presence of secretory IgA at the mucosal surfaces is mainly a result of active transport by 
polymeric IgA receptors (pIgR) through the epithelium (174-176). The IgG is also 
detected in human and animal mucosal secretions and neonatal Fc receptor for IgG 
(FcRn) is responsible for IgG transport (177-179).  
  




lavage (BAL) fluids from human patients with allergic rhinitis and bronchial asthma 
(180-182) and is detected in nasal washes from allergic patients receiving nasal challenge 
with specific allergens (180, 182, 183). The functional significance of IgE in airway 
secretions and mechanism by which IgE is transported to airway secretions are not well 
understood. IgE synthesis and heavy chain class switching to IgE occur in B cells from 
the nasal mucosa of allergic individuals (184). Such allergen-specific plasma cells rest in 
lymphatic organs and can secrete large amounts of IgE antibodies over several yars nd 
in the complete absence of allergen (185).  
 
Microbial infection and asthma  
Several respiratory viruses and bacteria have been shown to cause exacerbations 
of asthma (186-191). Virus-induced wheezing in infancy is a risk factor for asthma, and 
recent studies have highlighted the role of viruses in causing acute illnesses and being a 
possible contributing factor to chronic asthma. For example, human rhinoviruses (HRVs) 
is considered as the most common cause of the common cold in infants and children 
(192- 194). Atypical bacterial infections from Mycoplasma pneumoniae and Chlamydia 
pneumoniae have also been linked to chronic asthma and potential asthma exacerbations. 
The respiratory syncytial virus (RSV) and influenza virus appears to promote specific 
responses that, on their own, can cause severe pulmonary problems (195-199). However, 
the pathogenic microbiologic mechanisms involved in this link with asthma have not 
been well characterized.  
 




 Asthma is a chronic inflammatory disorder of the airways and Th2 inflammation 
is a key feature of asthma. Immunotherpeutic approaches are proposed and target Th2-
type effector cytokines, Th2 cell recruitment and development (1). Alternative strategies 
use the immunomodulatory potential of tolerance-inducing cytokines such as IL-10 or of 
cytokines such as IL-12, IL-18 and IFN-γ that are able to induce a counter-balancing Th1 
immune response. These are likely to be due to an allergen-blocking effect at the mast 
cell level and/or at the level of the antigen-presenting cell that prevents IgE-facilitated 
activation of T cells. In addition, blocking the effects of IgE or CD23 has also been 
shown to be an effective strategy in the treatment of allergic asthma (1). Therapeutic 
effect of anti-IgE treatment for allergic disease is based on the ability of anti-IgE 
antibodies to form immune complexes with free IgE, reducing the degranulatio  of mast 
cells and basophils. For example, Omalizumab is an effective humanized anti-IgE mAb 
showing promising results in controlling allergic inflammation (200). In addition, 
immunotherapy targeting CD23 molecule with Lumiliximab (IDEC-152) a primatized 
human anti-CD23 antibody with primate variable region and human constant region is 
safe and has potential therapeutic effect in the Phase I clinical trial for controlling allergic 
diseases (201).    
 
SPECIFIC AIMS  
Epithelial cells lining the airway, in addition to function as a barrier, are likely to 
play a more critical role in the initiation of airway allergic inflammation, as shown by 
increased release of inflammatory mediators and expression of a variety of immune 




patients with allergic rhinitis and bronchial asthma. For many years, the presence of IgE 
in airway secretions has been simply considered as IgE transuded passively from the 
serum. The complete paucity of mechanistic studies IgE transport in airway has seriously 
hampered the understanding of allergic inflammation in the lung. CD23, an IgE receptor, 
is shown to regulate IgE synthesis in B lymphocytes and transport IgE across the 
polarized intestinal epithelial cells during food allergies and infections. Here, we reason 
that CD23 may also be expressed in the airway epithelial cells regulating IgE transport. 
Therefore Specific Aim 1 is to define the role of CD23 expression and CD23-
mediated IgE transport in the respiratory tract.  
Similarly, IgE and immune complexes were found to be a potent inflammatory 
mediator in the murine airway tract during asthma development. Therefore, Specific Aim 
2 is to determine the CD23-mediated IgE/allergy transport and the roles of such 
transport in asthma development in a murine model.  
CD23 can transport IgE across polarized epithelium. To take advantage of this 
unique transport pathway, we hypothesized that CD23 may deliver CTLA-4, a negative 
regulator of T cell immune response, fused to IgE Fc fragment across epithelial barrier to 
serve as immunotherapeutic purpose for asthmatic allergy. Therefore, the Specific Aim 3 
is to determine the feasibility of CD23 to deliver IgE Fc-fused proteins across airway 
barrier and further the effect of this fusion protein on the development of allergic 








CHAPTER 2: CD23 DEPENDENT TRANSCYTOSIS OF IGE AND IMMUNE 
COMPLEX ACROSS THE POLARIZED HUMAN RESPIRATORY EPITHELIAL 
CELLS 
(Previously published as: Palaniyandi S, Tomei E, Li Z, Conrad DH, Zhu X. CD23-
dependent transcytosis of IgE and immune complex across the polarized human respiratory 
epithelial cells. J Immunol. 2011,186:3484-96). 
ABSTRACT 
       IgE-mediated allergic inflammation occurs when allergens cross-link IgE’s on the 
surface of immune cells, thereby triggering the release of inflammatory mediators as well 
as enhancing antigen presentations. IgE is frequently present in airway secretions and its 
level can be enhanced in human patients with allergic rhinitis and bronchial asthma. 
However, it remains completely unknown how IgE appears in the airway secretions. In 
this study, we show that CD23 (FcεRII) is constitutively expressed in established or 
primary human airway epithelial cells and its expression is significantly up-regulated 
when airway epithelial cells were subjected to IL-4 stimulation. In a transcytosis assay, 
human IgE or IgE derived immune complex was transported across a polarized Calu-3 
monolayer. Exposure of the Calu-3 monolayer to IL-4 stimulation also enhanced the 
transcytosis of either human IgE or the immune complex. A CD23 specific antibody or 
soluble CD23 significantly reduced the efficiency of IgE or immune complex 
transcytosis, suggesting a specific receptor-mediated transport by CD23. Transcytosis of 
both IgE and the immune complex was further verified in primary human airway 
epithelial cell monolayers. Furthermore, the transcytosed antigen-IgE complexes w re 
competent in inducing degranulation of the cultured human mast cells. Since airway 
epithelial cells are the first cell layer to come into contact with inhaled lergens, our 




a critical role in initiating and contributing to the perpetuation of airway allergic 
inflammation.    
 
INTRODUCTION 
 Allergic diseases are the most common type of all immunologically mediated 
disorders affecting 20–30% of the U.S. population and are increasing in incidence in the 
developed world (202). Airway allergy is one type of allergic disorder that affects both 
adults and children. Typically, the allergic inflammation in the airway is characterized by 
a prominent increase in the numbers of immune cells, such as eosinophils, and an 
imbalance between the Th1 and Th2 cells mediated immune response with a shift 
towards Th2 cytokine release, such as IL-4, IL-5, and IL-13 and the considerable increase 
of allergen-specific IgE (1, 180, 203). IL-4 and IL-13 can further promote B cell class
switch to increase IgE production (1, 204, 205). IgE is considered a major player in 
airway allergic inflammation. Clinical studies have found a close association between 
asthma and serum IgE levels and the amount of allergen specific IgE can be dramatically 
increased in sensitized or atopy patients (206, 207). Allergen-specific IgE is located in 
the human airway, such as in nasal mucosal from allergic patients who suffer allergic 
rhinitis in sinonasal tissue, nasal polyposis, and allergic fungal rhinosinusitis (181, 208-
210). This observation is further supported by the fact that B cells from the nasal mucosa 
of allergic individuals locally synthesize IgE (184, 211). As a result, allergen-sp cific IgE 
consistently appears in airway fluids in asthmatic patients obtained with or without 
bronchial provocation with the allergen. The proposed role of IgE in the initiation of the 
asthmatic allergy is that the allergy is triggered by antigens cross-linking IgE bound to 




cells which releases potent inflammatory mediators (1, 202). In the airway mucosa, these 
inflammatory mediators, including histamine, lipid mediators, proteases, etc, can act on 
nearby cells, such as epithelial cells and smooth muscle cells and further cause airway 
obstruction. However, in order for inhaled allergens to gain access to immune effector 
cells in the lamina propria, they must first cross the respiratory epithelium containing 
ciliated columnar, mucus-secreting goblet and surfactant secreting Clara ce ls. These cells 
can form a highly regulated and impermeable barrier made possible through the 
formation of tight junctions localized in the apical part of the columnar cells. In general, 
tight junctions prevent the free uptake and passage of macromolecules such as IgE and 
allergens. Hence, the exact mechanisms responsible for the cross-talk between 
allergen/IgE and immune effector cells in the airway remains poorly understood.  
Two receptors for IgE, high affinity receptor FcεRI and low affinity receptor 
FcεRII (CD23), play important roles in the pathogenesis of airway allergic inflammation. 
FcεRI present in airway mast cells is sensitized by the allergen-specific IgE upon 
exposure to a specific allergen. FcεRI is activated to signal for the production of potent 
mediators that are responsible for clinical symptoms in allergic diseases (17). In humans, 
CD23 has two isoforms-CD23a and CD23b. The amino acid sequences of the CD23a and 
CD23b proteins differ only in their 6/7 N-terminal residues, a region that corresponds to 
the cytoplasmic domains (76, 130), suggesting that this region regulates divergent 
intracellular trafficking and/or signaling pathways. Unlike FcεRI, both CD23 isoforms 
exhibit a type II membrane glycoprotein structure with a carboxyl terminal C-type lectin 
head that binds IgE in a calcium-independent manner (18). Although CD23 monomers 




which enables CD23 to bind IgE with higher-affinity (1, 61, 130). More interestingly, the 
stalk region of CD23 is susceptible to proteolysis by enzymes, such as the 
metalloproteinase ADAM10, to release various soluble CD23 fragments (sCD23) (104-
106). Soluble CD23 also has IgE binding activity (212) and its level is increased in 
allergies (157). CD23 is constitutively and inducibly expressed in variety of cell typ s, 
including B cells, eosinophils, monocytes and Langerhans cells (76, 77, 82, 164). More 
interestingly, CD23 has various functions, such as mediating B cell growth, enhancing 
IgE mediated antigen presentation (122, 213), and regulating IgE homeostasis (63, 64, 
125, 127). 
The functional significance of IgE found in the mucosal secretions of the human 
airway remains elusive. Several elegant studies have demonstrated a potential function 
for CD23 to transport IgE and IgE-derived immune complex across the polarized human
intestinal epithelial monolayer (143-145). Furthermore, the facilitated transport of IgE 
and uptake of antigens by CD23 are essential steps in the initiation of rapid allergic 
inflammation in the intestine in a murine model (140, 141). All these experiments suggest 
a role of CD23-mediated IgE transport in food allergy. However, it remains completely 
unknown if a similar mechanism of transport of IgE or immune complex exists in human 
airway epithelium.  If such a function exists, allergen-specific IgE in the airway may 
capture airborne allergens and form immune complexes in human airway tract. 
Subsequently, because of the especially sensitive environment of the airway tract, these 
immune complexes may function as more potent inducers or triggers of immune 
responses in the airway and thus, contribute to he perpetuation of airway inflammatory 




variety of epithelial cells derived from human airway. Most importantly, CD23 was 
capable of transporting human IgE or IgE-derived immune complex across polarized 
human airway epithelial monolayers. By mimicking the allergic conditions, we also 
demonstrated that epithelial cell exposure with IL-4 resulted in the up-regulation of CD23 
expression accompanied by enhanced transepithelial transport of IgE and, more 
importantly, of IgE-derived immune complexes. These transported immune complexes 
were then capable of inducing the degranulation of human mast cells. Our findings may 
provide important evidences that CD23 in human airway epithelial cell is very lik l to 
have a pivotal role in the initiation and development of airway allergic inflammation.   
 
MATERIALS AND METHODS 
Antibodies, cells and reagents.  
The human airway epithelial cell lines A549 and Calu-3, intestinal epithelial cell 
line HT-29, and monocytic cell line U937 were purchased from the American Type 
Culture Collection (ATCC, Manassas, Virginia). The human nasal epithelial c l Detroit 
562 was a gift from Dr. Jing-Ren Zhang (Albany Medical School, NY); human bronchial 
epithelial cell line 16HBE14o- was from Dr. Dieter Gruenert (University of California, 
SF). Human B cell line RPMI8866 was from Dr. Lance Bridges (University of Central 
Arkansas, AK). T84 cells stably expressing human CD23b was a gift from Dr. Cecilia 
Berin (Mount Sinai School of Medicine, NY). The cells were cultured in DMEM 
complete medium containing 10% FBS, 1% L-glutamine, non essential amino acids, 
100U/ml penicillin and 100 µg/ml streptomycin. U937 and RPMI 8866 cell line were 




by Drs. Arnold Kirshenbaum and Dean Metcalfe (National Institutes of Health, Bethesda, 
MD) and grew in serum free growth medium Stem Pro-34 containing 100 ng/ml of stem 
cell factor. EpiAirway (AIR-100) tissue model containing normal human trache l 
bronchial epithelial cells were obtained from MatTek Corporation (Ashland, MA).  The 
cells were cultured in AIR-100 medium according to the manufacturer’s instruction. All 
cells were grown in a humidified atmosphere of 5% CO2 at 37ºC.  
NP-BSA, 4-hydroxy-3-nitrophenylacetyl (NP) hapten conjugated to bovine serum 
albumin (BSA), was purchased from Biosearch Technologies (Novato, CA). The anti-
human CD23 Ab-secreting murine hybridoma EBVCS1 (67, 214) was a kind gift from 
Dr. Bill Sugden (University of Wisconsin-Madison, WI). Human IgE was purchased 
from Scripps (LaJolla, CA), human IgE containing kappa light chains was from Abbiotec 
(San Diego, CA). Goat anti human IgE and mouse IgG1 were purchased from Sigma 
Aldrich (St Louis, Mo). Antibody against human IL-4 receptor, chimeric anti-NP IgE, 
chimeric anti NP-IgG, and mouse anti-human CD23 Ab clone Tu1 were obtained from 
AbD Serotec Inc (Raleigh, NC). JW8 cells secreting the NP-specific human IgE were 
obtained from Dr. Hannah Gould (Kings College, London). Mouse anti human IgE, 
mouse anti-human tryptase specific antibody was from Abcam (Cambridge, MA). 
Recombinant IL-4 and soluble CD23 were purchased from R & D Systems (Minneapolis, 
MN). Proteinase inhibitor cocktail was obtained from Calbiochem (San Diego, CA). The 
CD23bHA plasmid was received from Dr. Zena Werb (Univeristy of California-San 
Francisco, CA). Antibody IDEC-152 was a gift from Dr. Marilyn Kehry (Biogen-Idec, 






                Semi-quantitative RT-PCR was performed as previously described (215). In brief, 
total RNA was isolated from stimulated human IL-4 (20 ng/ml) and mock-stimulated cells 
(2 x 106/ml) in TRIzol reagents (Invitrogen) according to the manufacturer’s instructions. 
RT-PCR was performed using a one-step RT-PCR kit (Qiagen). Negative control was set 
without RNA template.  Primers for amplification of CD23a and CD23b (145) and 
gylceraldehyde-3-phosphate dehydrogenase (GAPDH) (215) have been previously 
described. For the amplification of CD23 mRNA, 150 ng of total RNA was used. For IL-4 
stimulation, 5 ng total RNA from U937 and 40 ng total RNA from A549 or Calu-3 was used 
for amplification. Thirty-six cycles of PCR amplification were performed in a 20-µl volume. 
Each cycle consisted of denaturation at 94°C for 30 s, annealing at 55°C for 30 s, and 
extension at 72°C for 20 s. An additional 10 min was applied for the final extension. PCR 
products were resolved on 1.5 % agarose gels and visualized by ethidium bromide staining. 
Integrated density values for CD23 band intensities were analyzed by densitometry using 
Adobe Photoshop and normalized to the GAPDH values to yield a semi-quantitative 
assessment. 
 
Gel electrophoresis and Western blotting.  
                Gel electrophoresis and Western blot were performed as previously described 
(215). Protein concentrations were determined by the Bradford method. The cell lysat s
were subjected to 12% SDS-PAGE gel electrophoresis under reducing conditions. 
Proteins were electrotransferred onto a nitrocellulose membrane (Schleicher & Schuell). 
The membrane was blocked with 5% skim milk powder in PBS. The membranes were 




HRP-conjugated rabbit anti mouse Ab (Pierce). For detecting human IgE, membran s 
were probed with HRP conjugated goat anti human IgE Ab. For detecting NP antigen i  
NP-BSA, membranes were first incubated with chimeric anti-NP IgG followed by HRP 
conjugated rabbit anti human IgG Fc. All blocking, incubation, and washing were 
performed in PBST solution (PBS and 0.05% Tween 20). Proteins were visualized by an 
ECL method (Pierce).  
 
Flow cytometry.  
                Surface and intracellular expression of human CD23 was examined in either 
fixed or permeabilized A549 or RPMI 8866 cells by flow cytometry. For staining, 1 X 
106 cells were washed with FACS washing buffer (2% FBS in PBS) and followed by 
blocking with PBS containing 3% normal goat sera (Rockland, Gilbertsville, PA)/PBS on 
ice for 20 min. For surface CD23 staining, the cell suspensions were incubated with anti 
CD23 EBVCS1 or isotype-matched mouse IgG1 (1µg/ml) for 30 min, washed and further 
incubated with Alexa flour 488 conjugated goat anti mouse (1:500) antibody at 4°C. 
Surface staining was carried out at 4°C to minimize internalization. For intracellular 
staining, the cells were first permeabilized and fixed with Cytofix/Cytoperm (BD 
Pharmingen) on ice for 20 min, then washed with washing/permeabilization buffer and 
blocked with 3% normal goat serum.  The cells were further incubated with EBVCS1 
antibody (1µg/ml) diluted in washing/permeabilization buffer, washed and incubated 
with Alexa fluor 488 conjugated goat anti mouse (1:500) antibody. After washing, cells 






                 Immunocytochemistry was performed as previously described (216). The 
epithelial cells were grown on coverslips to 70-80 % confluence overnight or in transwell 
inserts to allow polarization. The cells were rinsed in cold PBS and cold-fixed in 4%
paraformaldehyde in PBS for 20 min at 4°C. The cells were washed and quenched with 
100 mM glycine for 10 min. After washing, the cells were permeabilized for 30 min with 
0.1% Triton X -100 and blocked with 3% normal goat serum. Cells were incubated with 
affinity purified anti-CD23 EBVCS1 Ab (1µg/ml) in PBST (0.05% Tween 20/PBS) or 
mouse anti-human IL-4 receptor Ab with 3% normal goat serum in PBS for 1 hr, and 
further incubated with Alexa flour 488 conjugated goat anti mouse antibody (1:500). The 
cells grown in the transwell were stained using procedures above with the addition of 
antibodies on both sides. Finally membrane was cut from the transwell and mounted on 
the slide and analyzed. Negative control was performed by incubating the isotype-
matched normal mouse IgG1 Ab. Cell nuclei were counterstained with DAPI (0.5 g/ml, 
Molecular Probes) in PBS. After each step, cells were washed with 0.1% Tween-20 in 
PBS. The ProLongTM antifade kit was used to mount coverslips (Molecular Probes). The 
images were taken using a Zeiss LSM510 laser scanning confocal microscope (Zeiss 
Microimaging Inc., NY).  
 
Enzyme-linked immunosorbent assay (ELISA).  
                The IgE concentration was measured with ELISA. ELISA plates (Nunc) were 
coated with rabbit anti human IgE Ab (10 µg/ml) overnight at 4ºC. Plates were then 




for 1 hr at room temperature. The transcytosed samples or IgE standards diluted in 10% 
FBS in PBS were incubated for 2 hr at room temperature. Mouse anti human IgE 
(1:10,000, Abcam) and HRP conjugated rabbit anti mouse antibody (1:10,000, Pierce) 
were used for detection of human IgE. For detection of chimeric IgE, HRP conjugated 
goat anti-human IgE (1:10,000, Sigma) was used. A colorimetric assay was done with 
tetra methyl benzidine (TMB) and hydrogen peroxide and a Victor III microplate reader 
(Perkin Elmer).  
 
Transcytosis assay.  
               Transcytosis was performed as previously described with modifications (145, 
177, 215). Calu-3 cells (1 × 105/ml) were grown onto 0.4 µm-pore size transwell inserts 
(BD Bioscience) to form a monolayer exhibiting transepithelial electrical esistances 
(TER, 450-900 Ω/cm2). TER was measured using a tissue-resistance measurement 
equipped with planar electrodes (World Precision Instruments, Sarasota, FL). Monolayers 
were equilibrated in serum free DMEM or stimulated with human IL-4 (20 ng/ml) for 24 
hr. The pseudo-stratified normal human tracheal bronchial epithelial tissue (AIR-100) 
had a TER at least 450 Ω/cm2 during transcytosis assay. For Western blotting analysis, 
human IgE or chicken IgY was added either to apical (25µg/250µl) or basolateral 
(50µg/500µl) side. However, when ELISA is used for detecting transcytosis, the IgE 
amount loaded was lowered to 5µg/250µl in the apical side or 10µg/500µl in basolateral 
side, respectively. For IgG transcytosis, human IgG (125µg/250µl) was added to the 
apical chamber. They were incubated at 37ºC for 2 hr. In addition, protein L beads 




transcytosis. The immune complex or NP-BSA antigen alone (10 µg/ml) was added to 
apical chamber and incubated at 37ºC for 30, 60, 120 min. The immune complex was 
formed by incubating chimeric anti NP IgE (20 µg/ml) with NP-BSA (10 µg/ml) at 37ºC 
for 45 min. For negative control, monolayers were also incubated at 4ºC for 2 hr before 
transcytosis. The media from the opposite chambers were collected and concentrated 
using ultracel YM-10 (Millipore, Billerica, MA). Transported proteins were analyzed by 
reducing SDS-PAGE and Western blot-ECL for detection of NP antigen, IgG, IgE and 
chicken IgY. IgE was also detected with ELISA. Adobe Photoshop was used to 
determine relative band intensities of a blot.   
 
Mast cell degranulation assay.  
                 Mast cell degranulation assay was performed as previously described with 
modification (217). The Calu-3 cells were allowed to get polarized in the transwell insert. 
Immune complex, antigen alone, and human IgE were respectively added into the apical 
chamber and transcytosis were performed at 37ºC for 3 hr. Human mast cell line LAD2 
was cultured with media in the basolateral chamber and allowed to capture the 
transported immune complex, antigen or human IgE.  In addition, prior to the addition of 
the transcytosed immune complex, LAD2 cells were also primed with or without 200 
ng/ml NP specific IgE or antigen non specific IgE. The degranulation assays were 
performed in a 96 well plate. Tryptase or β-hexosaminidase was measured in 100 µl 
supernatants as indicator of mast cell degranulation.  As a positive control, immune 
complexes were directly added to the LAD2 cells for 1 hr. β-hexosaminidase was 




mol/L phosphate buffer (pH 4.5) as substrate for incubation at 37ºC for 1 hr. The reaction 
was terminated with a 2-M glycine solution (pH 10.7). Tryptase was measured by adding 
the substrate 1 mM N-Tosylglycyl-L-prolyl-L-lysine 4-nitroanilide dissolved in 50 mM 
Tris-HCl (pH 7.6), 120mM NaCl and 20 µg/ml heparin solutions and incubated for 1 hr 
at 37 °C.  To quantify the substrate cleavage, the absorbance at 405 nm was measured 
using a microplate reader. The results were read out at 405 nm. In addition, tryptase in 
LAD2 mast cells was analyzed by immunofluoresence staining with human tryptase 
specific antibody in a confocal microscope.  
 
Statistics.  
                 The statistical difference between groups was tested by Student t test. A P value 
of less than .05 was considered significant. Data are expressed as mean ± SD. 
 
RESULTS 
Human respiratory epithelial cells express CD23.  
              Epithelial cell lines from human nasal, trachea, and lung were used in studies on 
human CD23 expression. These cell lines maintain the differentiation characteristics of 
their tissues of origin with proper polarity. Human CD23 is expressed in two isoforms: 
CD23a and CD23b (145). Results from RT-PCR amplification showed that all airway 
epithelial cells expressed the CD23b (Fig. 2.1A), but not the CD23a (Fig. 2.1B), 
transcript. Mononuclear cell line U937 was used as a positive control. The PCR products 
were sequenced to verify CD23b isoform specific transcript. To verify CD23 expression 




with EBVCS1 mAb, a specific IgG1 Ab for human CD23 (67, 214). These airway 
epithelial cells expressed protein bands identical to 293T and intestinal T84 cells 
transfected with vectors expressing human CD23b cDNA in a Western blot (Fig. 2.1C, 
left panel). Two bands were identified; however, the top band (50 kDa) was also 
expressed in cell lysates from Chinese hamster ovary (CHO) cell lysates (Fig. 2.1C, right 
panel), suggesting the lower band (45 kDa) is CD23 specific. In addition, 
immunofluorescence staining of Calu-3 cells by EBVCS-1 mAb (Fig. 2.1D, left panel), 
but not for isotype-matched IgG1 Ab (Fig. 2.1D, right  panel), revealed the expression of 
CD23 protein. 
 CD23 is known to be expressed intracellularly and/or at the cell surface (218). To 
show the expression pattern of CD23 in airway epithelial cells, we stained lung epithelial 
cells A549 with EBVCS1 mAb for cell surface or intracellular expression by flow 
cytometry (Fig. 2.1E). The specificity and expression pattern of CD23 was, in parallel, 
performed in a RPMI 8866 human B cell line. In contrast, to approximately 84% human 
B cell line, only about 36% A549 cells expressed CD23 at cell surface. However, 
permeabilization of A549 cells revealed substantial increases of CD23 positive cells from 
approximately 36% to 99%. The distinct cellular distribution of CD23 between airway 
epithelial and B lymphocytes has not been appreciated in previous study. In addition, 
activation of human eosinophils leads to increased surface expression of CD23 (218). 
Our data showed that IL-4 stimulation also increased the surface expression of CD23 in 
A549 cells (data not shown). Therefore, we conclude that CD23 is mainly expressed 
intracellularly in lung epithelial cell A549, suggesting CD23 may function as an 




















Figure 2.1 Human airway epithelial cell lines express CD23.  
(A + B) CD23b, but not CD23a, isoform was expressed in human airway epithelial cells. 
Total RNA was extracted by TRIzol reagent from airway epithelial cells Detroit 562 
(lane 4), 16HBE14o- (lane 5), Calu-3 (lane 6), A549 (lane 7). Monocyte cell line U937 
(lane 2) and intestinal epithelial cell HT-29 (lane 3) were used as a positive control. RT-
PCR was performed by using CD23a or CD23b isoform specific primers as described in 
Materials and Methods. Amplified PCR products, 170 bp for CD23a and 131 bp for 
CD23b, were electrophoresed in 1.5% agarose gel and stained with ethidium bromide. 
NC represents a negative control without template in RT-PCR reaction. Similar PCR 
products amplified with a GAPDH-specific primer pair was used as internal co trols. The 
arrow indicates the location of the amplification products for CD23 and GAPDH. The 
molecular weight in base pairs (bp) is indicated on the left.  
(C) CD23 protein was expressed by human airway epithelial cells. The cell lysates (60 
µg) from 293T-CD23bHA (lanes 1 & 7) and T84-CD23b (lane 2), Detroit 562 (lane 3), 
Calu-3 (lane 4), A549 (lane 5), and CHO (lane 6) were separated by electrophoresis on 
12% SDS-PAGE gel under reducing conditions. The proteins were transferred onto 
nitrocellulose membrane and blotted with mouse anti-human CD23 EBVCS1 mAb. The 
blots were incubated with HRP-conjugated rabbit anti-mouse IgG and the protein bands 
were visualized by ECL method.  The arrow indicates the location of the CD23.  
(D). Immunofluorecence staining of Calu-3 cell line. The Calu-3 cells were grown on 
glass coverslips, fixed with 4% para-formaldehyde and permeabilized in 0.1% Triton X-
100. Subsequently, the cells were incubated with goat serum for blocking and affinity-
purified mouse anti-CD23 EBVCS1 mAb, followed by staining with an alexa flour 488-
conjugated goat-anti mouse antibody. The Calu-3 cell was stained with an isotype
matched mouse IgG1 Ab as negative control (right panel). The nucleus was stained with 
DAPI and photographed through a fluorescence microscope. Samples were viewed using 
the same contrast and brightness settings. 
(E). Cellular distribution of human CD23 expression patterns in lung epithelial cell and B 
lymphocytes. Cell surface and intracellular expression patterns of CD23 in either fixed or 
permeabilized lung epithelial cell A549 and B lymphocyte RPMI 8866 were measured by 
flow cytometry analysis. Cells were stained as described in the Materials and Methods. 
Results are expressed as histograms of fluorescence intensity (log scale). The histograms 
represent staining of cells with anti-CD23 EBVCS1 mAb or isotype-matched mouse 
IgG1 and then with Alexa fluor 488 conjugated goat anti mouse IgG Ab. Values in each 
rectangle correspond to the proportion of cells stained with the anti-CD23 Ab relative to 








IL-4 stimulation up-regulates the expression of CD23 in human airway epithelial cells.  
                 The Th2 type T cells mediate airway allergic inflammation by producing IL-4 
and IL-13. IL-4 and IL-13 can enhance the expression of CD23 in both B cells, 
monocytes, and intestinal epithelial cells (219, 220). The results showed that when 
airway epithelial cells A549 and Calu-3 cells were subjected to IL-4 (20 ng/ml) 
stimulation for 24 hr, CD23b mRNA expression, which was measured by semi-
quantitative RT-PCR, was significantly enhanced (Fig 2.2A, lanes 5 & 7). In contrast, 
CD23a mRNA expression was not induced by 24 hr IL-4 stimulation in A549 and Calu-3 
cells (Fig. 2.2B, lanes 5 & 7). As expected, mRNA expression of both CD23a and CD23b 
isoforms in U937 were significantly enhanced after IL-4 stimulation.  Furthermor , as 
shown in Fig. 2.2C, expression of IL-4 receptor was shown by immunofluorescence 
staining with IL-4 receptor mAb, but not with isotype matched IgG antibody when Calu-
3 cells were grown in transwell inserts and polarized.  
 
CD23 transports human IgE bidirectionally across the polarized Calu-3 epithelial cells. 
                 The human airway epithelial cell, Calu-3, was polarized and used to 
transcytose IgG bidirectionally when grown on both sides of filter supports (215). Hence, 
we used Calu-3 as a model cell line to examine transcytosis of human IgE. First, CD23 
expression was verified by immunofluorescence staining with EBVCS1 mAb when Calu-
3 cells were grown on 0.4 µ pore size inserts (Fig. 2.3A). CD23 staining was mainly on 
the brush border apical membrane with some staining also evident on the basolateral 
membrane. To show interaction of CD23 and IgE within the Calu-3 cells, IgE (0.5 





Figure 2.2 CD23 expression was up-regulated in human airway epithelial cells 
following exposure to IL-4 treatment.  
(A + B). Human airway epithelial cells Calu-3 and A549 were incubated with or without 
IL-4 (20 ng/ml) for 24 hrs. Monocytic cell line U937 was used as a positive control. At 
the end of incubation period, the cells were washed and total RNA was extracted by 
TRIzol reagent.  Total RNA was subjected to semi-quantitative one-step RT-PCR with 
CD23b (A) or CD23a (B) specific primers. GAPDH was used as internal control. PCR 
products were run in 1.5% agarose gels and stained with ethidium bromide. Densitometry 
analysis of CD23b (A, right panel) or CD23a (B, right panel) band intensities which 
were normalized to GAPDH was presented. NC: a negative control without template 
RNA in RT-PCR reaction. *P<0.05, **P<0.01.   
(C). Confocal microscopy detection of IL-4 receptor. Calu-3 cells (1 × 105/ml) were 
grown on 0.4 µm pore size inserts. Calu-3 cells were polarized, fixed and permeabilized 
in 0.1% Triton X-100. IL-4 receptor was detected by immunostaining with Alexa flour 
488 (green). Cells were stained with ZO-1 (red) to show the level of the tight junction 
and DAPI to stain nuclei (blue). The XY sections are taken at the level of the ZO-1 
staining, and the XZ sections are shown at the bottom. The red staining indicates the tight 





CD23 (green) and IgE (red) were co-localized (merged yellow). To show whether Clau-3 
cell transcytoses IgE, human IgE was added either to apical or basolateral sid  and 
further incubated at 37ºC for 2 hr. As a negative control, the Calu-3 cells were also 
incubated at 4ºC for 2 hr. The results showed that intact IgE applied to either apical (Fig. 
2.3C, lane 3) or basolateral (Fig. 2.3C, lane 4) chamber was transported in the opposite 
directions across the Calu-3 monolayer as assessed by blotting of IgE heavy c ain. 
Transport of IgE was not detected in monolayers incubated at 4°C (Fig. 2.3C, lane 2), 
ruling out the leaking possibility of IgE Ab across Calu-3 monolayers. Since CD23 was 
able to transport IgE bidirectionally across the polarized epithelial cells, w  also 
employed protein L beads that can specifically bind to kappa light chain IgE Ab in order 
to prevent the transcytosed IgE Ab from re-entering the transcytosis. This trapping 
method increased sensitivity and allowed ELISA to detect 1-1.5 ng IgE Ab that was 
transcytosed bidrectionally when either 75 ng or 150 ng of IgE was applied in apical or 
basolateral chamber respectively (Fig. 2.3D). It should be noted that this IgE Ab 
concentration represented a physiological level of IgE Ab in human sera although t e 
amount of allergen specific IgE can be considerably augmented in sensitized or atopy 
patients.  It remains to be known exactly how CD23 transports IgE Ab across the airway 
epithelial cell monolayers. 
It is possible that expression of FcεRI in airway epithelial cells may result in IgE 
transcytosis. To exclude this possibility we performed RT-PCR analysis for the 
expression of the alpha chain of FcεRI. Our results showed that airway epithelial cells 
failed to express FcεRI (data not shown) at 35 cycles of PCR amplifying condition. To 




two experiments were performed. First, IgE incubation with soluble CD23 (sCD23) 
significantly inhibited the amount of IgE transcytosed (Fig. 2.3E). Second, either apically 
or basolaterally-applied CD23 specific Ab IDEC152 (1 µg/ml) significantly inhibited the 
transcytosis of IgE from the apical to basolateral (Fig. 2.3F) or vice versa(data not 
shown). IDEC-152 mAb is anti-human CD23 mAb (IgG1) consisting of primate 
(cynomolgus macaque) variable regions and human constant regions, for this reason, we 
did not include an isotype-matched IgG1 mAb as a control.  IDEC-152 has been shown to 
block synthesis of IgE from human B cells in vitro (201). The protein concentrations for 
block were previously determined in a serial dilution. Both experiments demonstrated the 
specificity of CD23-mediated IgE transport in Calu-3 cells. We further defined the role of 
endosomal trafficking in CD23-mediated IgE transcytosis. Calu-3 cell insrts were 
incubated with or without bafilomycin A1 (0.1 µmol), which interferes with the 
intracellular trafficking by inhibiting endosome acidification as shown in tra scytosis of 
IgE or IgG in intestinal epithelial cells (145, 177). As shown in Fig. 2.3G, bafilomycin 
significantly inhibited apical to basolateral IgE transcytosis although it was unable to 
completely block CD23-mediated IgE transcytosis. As an internal control, the 
bafilomycin completely blocked IgG transcytosis across Calu-3 monolayer, which is in 
agreement with the previous finding (Fig. 2.3H) (177).  Hence, we conclude that IgE 
entering both apically- and basolaterally-directed transcytotic pathways in lung epithelial 
cells is dependent on CD23 expression.  
 




                Previous studies have shown that IgE is frequently present in the mucosal 
secretions of airway tract and its level can be enhanced in human patients with asthma
(207, 209). Transferring of the intact allergen molecule across the airway epithelial 
barrier may be an important event in priming a host for an allergen and subsequent 
exposure of same allergen leads to the development of allergic inflammation. CD23 
mediated IgE transport across the polarized Calu-3 epithelial cells suggests all rgen-
specific IgE may also capture airborne allergen and form immune complexes in the lumen 
of airway tract.  Therefore, we further examined whether CD23 could facilitate 
transepithelial transcytosis of IgE-derived immune complex across Calu-3 monolayers. 
We used chimeric IgE that consists of mouse Fab directed against 4-hydroxy-3-
nitrophenylacetyl hapten (NP) molecules and human Fc fragment. Chimeric IgE can well 
bind to human CD23 as previously demonstrated (145). Immune complex was formed by 
incubating the chimeric IgE with NP-BSA at 37ºC. Transcytosis of immune complexes 
across polarized Calu-3 epithelial cells was examined from the apical (lumenal) to 
basolateral direction to mimic the in vivo shown in Fig. 2.4A, the apically applied IgE-
NP-BSA complex was transported after 2 hr in the basolateral direction acrss Calu-3 
monolayer at 37ºC incubation (lane 4), as assessed by blotting of NP antigen. Immune 
complex incubated at 4ºC (Fig. 2.4A, lane 2) condition where the airway epithelial cells 
are usually exposed to the inhaled antigens. As or NP-BSA antigen alone (Fig. 2.4A, lane 
3) was not transcytosed across polarized Calu-3 cells. The chimeric IgE in the immune 













Figure 2.3 CD23 transcytoses human IgE in Calu-3 cells.  
(A). Immunofluorecence staining of CD23 expression. Cells were grown on transwell insert, fixed and permeabilized in 0.1% 
Triton X-100. Subsequently, the cells were incubated with mouse anti-CD23 EBVCS1 mAb (green) and ZO-1 (red), followed 
by staining with Alexa flour 488 or 555 conjugated secondary Ab. The nucleus was stained with DAPI. The XY (top) or XZ 
(bottom) sections are taken.  
(B). Colocalization of CD23 and IgE in Calu-3 cell lines. Calu-3 cells were grown on transwell inserts. The cells were 
allowed to get polarized and the human IgE (0.5 µmol/L) was added to apical chamber and incubated at 37ºC for 30 min. 
Cells were stained by anti-CD23 EBVCS1 mAb and anti-human IgE Ab, followed by Alexa flour 488 or 555 conjugated 
IgG. CD23 (green) and IgE (red) were visualized by confocal microscope and yellow indicates the colocalization. 
(C). Calu-3 cells (1 × 105/ml) were grown on 0.4 µm pore size transwell inserts. The cells were allowed to get polarized and 
the transcytosis assay was performed when the TER value reached at least 450-900 Ω/cm2. The human IgE (0.5 µmol/L) was 
added either to apical or basolateral chamber and incubated at 37ºC for 2 hr. For blocking IgE transcytosis, the Calu-3 cells in 
individual inserts were incubated at 4ºC for 2 hrs. The IgE was subsequently added and transcytosis assay was performed for 
additional 2 hrs at 4ºC. The medium from opposite chamber was collected, concentrated and blotted to detect IgE heavy chain.  
A: apical; B: basolateral. 
(D) Effect of IgE concentration on the transcytosis. Human IgE at indicated concentrations were applied to the apical (75-2500 
ng/250 µl) or basolateral (150-5000 ng/500 µl) chamber and incubated at 37ºC for 2 hr. Protein L beads were used to 
specifically bind to the transported IgE Ab during transcytosis. The supernatants from the opposite chamber were collected at 
the end of 2 hr. The protein L beads were pull down, IgE was eluted and total IgE was measured by ELISA.   
(E + F). Effect of soluble CD23 (sCD23) or IDEC152 mAb on IgE transcytosis in Calu-3 cells. Human IgE was preincubated 
with sCD23 (E) and IDEC152 mAb was added to the transwell at 4ºC for 1 hr (F) before addition of IgE to the transwell at 
37ºC. The protein concentrations of either sCD23 or mAb were optimized in a pilot experiment. Transcytosis of human IgE at 
4ºC (lane 1) and 37ºC (lane 3) without sCD23 or IDEC152 mAb was used as control. Supernatant from the opposite transwell 
was sampled 2 hr later. Total IgE was measured by ELISA. Mean ± SD of three experiments is shown. 
(G + H). Calu-3 cells were incubated in the presence or absence of bafilomycin A1 (0.1 µM), and basolaterally directed 
transport of IgE and IgG was measured after 2 hr incubation. Transcytosed total IgE was measured by ELISA; total IgG was 





the immune complexes transcytosed across Calu-3 monolayer were detectable within 30 
min after transcytosis initiation (Fig. 2.4C, lane 3). The transcytosis of immune 
complexes was also decreased when the apically applied immune complexes were 
serially diluted (Fig. 2.4D, lane 3-4); however, non-linearity was detected between the 
applied immune complex and the transcytosis efficiency in the assay.  
 To further show whether this transport is dependent on CD23, two experiments 
were performed. First, we examined the influence of sCD23 on transcytosis of NP-BSA 
antigens in the presence of IgE. The incubation of soluble sCD23 with the immune 
complex before adding it to the Calu-3 monolayer significantly reduced the transcytosi  
of NP-BSA antigen in a sCD23 protein concentration (10-20 µg/ml) dependent manner 
(Fig. 2.4E, lane 4 & 5) in comparison with untreated immune complex at 37ºC (Fig. 2.4E, 
lane 3). This suggests that sCD23 renders the immune complex unavailable for 
membrane CD23 on the Calu-3 monolayer. Second, we determined that the transcytosis 
of the immune complex was significantly reduced by CD23-specific IgG Ab IDEC 152 
(Fig. 2.4F, lanes 3 & 4). In a parallel experiment, IgE in immune complex was also 
significantly reduced (Fig. 2.4G).  
 
IL-4 enhances the transcytosis of IgE or immune complex in polarized Calu-3 cells. 
                 IL-4 treatment enhanced CD23b expression in the airway epithelial cells (Fig. 
2.2). We further examined whether IL-4 treatment stimulates the transcytosi  of either 
IgE or immune complexes across the Calu-3 epithelial cells. To show this effect, the 
polarized Calu-3 monolayers were treated with or without IL-4 (20 ng/ml) exposure 















Figure 2.4 Transepithelial transport of immune complex in Calu-3 cells. Calu-3 cells (1 × 105/ml) were grown on 0.4 µm  
pore size transwell filters. The cells were allowed to get polarized and the transcytosis was performed when the TER value 
reached at least 450-900 Ω/cm2. The immune complex was formed by incubating chimeric anti-NP IgE (20 µg/ml) with NP-
BSA (10 µg/ml) at 37ºC for 45 min. A: apical; B: basolateral; STD: standard; IC: immune complex. 
(A+B). Transcytosis of immune complex (IC) in the Calu-3 cell line.  The NP-BSA Ag alone (lane 3) or IgE-NP-BSA immune 
complex (lanes 2 & 4) was added to the apical chamber for incubation at 4ºC (lane 2) or 37ºC (lanes 3 & 4) for 2 hr. The media 
from the basolateral chamber were collected and concentrated for detecting NP-BSA Ag in a Western blot (A) or total IgE in 
an ELISA (B). 
(C+D). Effect of incubation time or concentration of the immune complex on the transcytosis. Immune complex was added to 
the apical chamber at different time (C) or serially diluted with normal medium (D), and then incubated at 4ºC (lane 2) or 37ºC 
(C, lanes 3-5) or 37ºC (D, lanes 3-4) to allow transcytosis as indicated. The medium from the basolateral chamber was 
collected, concentrated, and blotted for detection of NP-BSA antigen.  
(E). Effect of soluble CD23 (sCD23) on the transcytosis of immune complex. Th  immune complex was preincubated with 
sCD23 at indicated concentration before addition to the apical chamber. Then, the immuneco plexes were incubated at 4ºC 
(lane 2) or 37ºC (lanes 3-6) for 2 hr to allow transcytosis. Supernatant from the basolater l chamber was sampled and blotted 
for NP antigen (E). The graph (E, bottom panel) represents the densitometry analysis of NP-BSA bands obtained from the 
transcytosed immune complex treated with (lanes 4-6) or without (lane 3) soluble CD23 proteins. Results were representative 
of three individual experiments. *P<0.05, **P<0.01.   
(F+G). Effect of CD23 specific Ab on the transcytosis of immune complex. CD23-specific IDEC152 mAb at indicated 
concentration was incubated with Calu-3 cells at 4ºC for 1 hr before the addition of immune complex to the apical chamber. 
Then, the immune complexes were incubated at 4ºC (lane 2) or 37ºC (lanes 3-5) for 2 hr to allow the IC transcytosis. 
Supernatant from the basolateral chamber was sampled and measured for NP antigen in a Western blot (F) or total IgE in an 
ELISA (G). The graph (F, bottom panel) represents the densitometry analysis of NP-BSA bands obtained from the 
transcytosed immune complex with samples treated with (F, lanes 3-4) or with ut (F, lane 5) IDEC152 Ab. Results were 





transcytosis of human IgE was significantly enhanced in both apical to basolateral (Fig. 
2.5A) and basolateral to apical (Fig. 2.5B) directions with IL-4 exposure at 37ºC in 
comparison with that of mock-treated cells. Kinetics of IgE transcytosis from the apical 
to basolateral direction in Calu-3 monolayer were shown in Fig. 2.5C. In a similar way, 
the transcytosis of IgE immune complex was also significantly enhanced in the presence 
IL-4 stimulation at 37ºC in comparison with that of mock-treated cells (Fig. 2.5D). The 
amount of IgE immune complex transported also exhibited a time course dependent 
manner (Fig. 2.5E). In addition, the immune complex was barely detectable when Calu-3 
monolayers were incubated at 4ºC (Fig. 2.5D, lane 2) suggesting Calu-3 cells under 24 hr 
exposure of IL-4 stimulation did not significantly alter the transepithelial resistance. 
Taken together, IL4 treatment increased the transcytosis of both IgE and immune 
complex across Calu-3 cells. 
 
Primary human tracheal and bronchial epithelial cells can transcytose both IgE and 
immune complex.  
                To further verify the transcytosis results of either IgE or immune complexes in 
human Calu-3 cell lines, we used commercially available primary human tracheal-
bronchial epithelial tissues which were originally obtained from a human donor. Human 
tracheal/bronchial cell cultures (EpiAirwayTM tissues, AIR-100-SNAP) closely resemble 
in-vivo conditions of human tracheal/bronchial cells. As the first step, CD23b, but not 
CD23a, expressions were verified by RT-PCR amplification with CD23 specific primers 














Figure 2.5 Effect of IL-4 treatment on transcytosis of IgE and immune complex in the polarized Calu-3 cells. Calu-3 
cells (1 × 105/ml) were grown on 0.4 µm pore size transwell filters. The cells were allowed to get polarized and the 
transcytosis was performed when the TER value reached at least 450-900 Ω/cm2. Calu-3 cells were treated with or without IL4 
(20 ng/ml) for 24 hr. A: Apical; B: Basolateral.  
(A+B). Human IgE (0.5 µmol/L) was added into the apical (A) or basolateral (B) chamber to allow transcytosis for 2 hr at 4°C 
(lane 2) and 37°C with or without IL-4 treatment (lanes 3 & 4). Supernatant from the opposite chamber was sampled, 
concentrated and blotted for IgE. The relative integrated band intensities of the IgE transcytosed across the Calu-3 monolayer 
from the top panel were calculated by densitometry analysis (bottom panels).  
C. Kinetics of IgE transcytosis in lung Calu-3 monolayer. Human IgE was added to the apical chamber of polarized Calu-3 
epithelial cells that were pretreated with (open circle) or without IL-4 (solid circle) for 24 hr and incubated at 37ºC for 
additional 2 hr at indicated time points. The medium from the basolateral chamber was collected and concentrated for 
measuring total IgE by ELISA. 
(D+E). IgE derived immune complex was added into the apical chamber to allow transcytosis for 2 hr at 4°C (lane 2) and 37°C 
in the presence or absence of IL-4 treatment (D, lanes 3 & 4). In panel E, Calu-3 monolayers were treated with IL-4 in 
indicated time (E, lanes 3-5). Supernatant from the basolateral chamber was sampled and blotted for NP-BSA antigen. The 
relative integrated band intensities of the immune complex transcytosed across the Calu-3 monolayer from the top panel were 




panel) with EBVCS1 mAb in these primary human epithelial cells. The specificity of the 
staining was confirmed with isotype matched IgG control (Fig. 2.6C, right panel). CD23 
expression was up-regulated in the primary human tracheal bronchial epithelial cells in 
response to IL4 treatment (data not shown). When human IgE was loaded onto either 
apical or basolateral chambers, these human primary tracheal-bronchial epit elial t ssues 
were capable of transcytosing IgE from either the apical to basolateral or the basolateral 
to apical directions (Figs. 2.6D+2.6E). IgE Ab failed to be detected in both directions 
when tissues were incubated at 4ºC. In addition, chicken IgY closely resembles human 
IgE in structure (221) was not transcytosed in both directions (Figs. 2.6D+2.6E) 
demonstrating that the human IgE detected in transcytosis assay was the specific 
transport, but not passively diffused through paracellular pathway or due to leakiness in 
model tissue.  To further show whether the primary human tracheal and bronchial 
epithelial cells can also transcytose immune complex, we incubated these cells with IgE 
derived immune complex in the apical chamber for 2 hr. As shown in Fig. 2.6F, antigen-
IgE complexes were transcytosed from the apical-to-basal at 37°C, but not at 4°C, s 
detected by Western blotting of NP-BSA antigens. Antigen NP-BSA alone was  
undetectable in transcytosis by primary human tracheal and bronchial epithelial cells 
further demonstrating the specificity of IgE-CD23 mediated transcytosis. Overall, all 
these evidences strongly indicate that IgE or immune complex can enter the transcy otic 









Figure 2.6 The primary human tracheal bronchial epithelial tissue transcytoses IgE and immune complex. All protein 
samples were separated on 12% SDS-PAGE gel under reducing condition, proteins transferred to nitrocellulose membrane, 
blotted with protein specific antibody, and followed by HRP conjugated secondary antibody. The blot was visualized by ECL 
method.  
(A) The primary normal human tracheal bronchial epithelial cells (TBEC, AIR-100) expressed CD23b but not CD23a mRNA. 
Total RNA was extracted by TRIzol reagent from primary epithelial cells that were grown in transwell inserts consists of 
TBEC forming highly differentiated and pseudo-stratified polarized epithelial tissue. The purified RNA was subjected to one 
step RT-PCR with CD23 specific primers. The PCR products were electrophoresed on 1.5% agaorse gel and DNA stained and 
identified with ethidium bromide. U937 cells (lane 2) were used as a positive control. NC, a negative control without RNA 
template in RT-PCR reaction. GAPDH was used as internal control.  
(B) CD23 protein was expressed in AIR-100 cells. The cell lysates (60 µg) from Calu-3 (lane 1), 293TCD23bHA (lane 2) and 
human tracheal bronchial epithelial cells (TBEC) (lane 3) 
 were subjected in a Western blot by blotting with mouse anti-CD23 EBVCS1 mAb. 
(C) Immunofluorecence staining of TBEC cells. The TBEC cells were removed from cultivated inserts by EDTA and allowed 
to grow on glass coverslips overnight, fixed with 4% para-formaldehyde and permeabilized in 0.1% Triton X-100. 
Subsequently, the cells were incubated with goat serum for blocking anti-human CD23 EBVCS1 mAb, followed by staining 
with an Alexa flour 488-conjugated goat-anti mouse Ab. The cells were also stained with an isotype-matched mouse IgG1 as 
negative control (right panel). The nucleus was stained with DAPI and photographed through a fluorescence microscope.  
(D+E). IgE transcytosis in primary TBEC. Polarized AIR-100 tissue from human donors grown on cell culture inserts was 
used. The cells were allowed to get polarized. The human IgE (left panel) or chicken IgY (right panel) (0.5 µmol/L) was added 
to either the apical (D) or basolateral (E) chamber and incubated at 37ºC (lanes 3 & 5) or 4ºC (lane 2) for 2 hr. The medium 
from opposite chambers was collected, concentrated and blotted to detect IgE or IgY heavy chain in a Western blot.  A: 
Apical; B: Basolateral. The image in Figure 6D was processed by the Photoshop. 
(F) Transcytosis of immune complex in primary TBEC. TBEC cells were grown on transwell filters. The cells were allowed to 
get polarized. The NP-BSA antigen alone (lane 3) or immune complex (lanes 2&4) was added to the apical chambers and 
incubated at 37ºC or 4ºC for 2 hr. The medium from the basolateral chamber was collected, conc ntrated, and blotted for NP to 




CD23-mediated transcytosis of immune complex induces human mast cell 
degranulation. 
                 IgE mediated hypersensitivity reactions are mediated by antigen cross-linking 
of IgE antibodies bound to its high affinity receptor (FcεRI) on immune cells, such as 
mast cells (1, 206). Because mast cells reside in close proximity to airway epithelial cells 
in the respiratory tract, we tested the ability of transcytosed antigen–IgE complexes to 
trigger the degranulation in human mast cells. To mimic the natural condition we cultured 
LAD2 cells (1 X 105/ml) in basolateral chambers when Calu-3 cells were grown in the 
transwell inserts. The LAD2, is an human mast cell analogue that can be stimulated to 
degranulate in an IgE-dependent manner (222). The supernatant from the basolateral 
chamber was obtained 3 hr later after apical addition of the immune complex, IgE, and 
antigen alone. Although mast cell degranulation occurs rapidly, the supernatant sampled 
3 hr after addition of the immune complex ensured enough antigens to be transported in 
the experiment. The degranulation of LAD2 cells were assessed by both tryptase and β-
hexosaminidase assays. As shown in Fig. 2.7A, as a positive control, direct incubation of 
LAD2 mast cells with immune complex induced high levels of mast cell degranulation. 
Also, LAD2 cells exhibited significant degranulation which was triggered by the 
transcytosed immune complex in comparison with that of IgE or antigen alone in either 
tryptase or β-hexosaminidase analyses. When LAD2 cells were primed with NP specific 
IgE prior to addition of the transcytosed immune complex, the level of degranulation was 
significantly enhanced in comparison with that of LAD2 cells primed with antige  non-
specific IgE Ab (Fig. 2.7A). The degranulation was also demonstrated by the 




was greatly reduced in the presence of the transcytosed immune complex in comparis n 
with IgE or antigen alone (Fig. 2.7B). However, it would be informative to use an antigen 
without multiple identical epitopes in degranulation assay. Therefore, IgE released from 
the airway epithelial cells together with the antigen in an immune complex form is 
capable of activating effector mast cells.  
 
DISCUSSION 
  The early inflammatory response during allergic rhinitis and asthma is strongly 
associated with inhaled allergens cross-linking specific IgE on the surface of mast cells, 
leading to their activation and release of primary inflammatory mediators (202, 223). The 
late phase reaction is characterized by recruitment, activation and tissue infiltration of 
leukocyte populations, including lymphocytes, eosinophiles, basophiles, and neutrophiles 
(1, 202). Antibody-antigen interaction in the airway drives early granulocyte recruitment 
(224). Recently basophiles were also found to function as antigen-presenting cells for an 
allergen-induced Th 2 response (225). Therefore, one of the major roles of the airway 
epithelium is to act as a barrier to restrict the antigens and other potentially noxious 
materials from penetrating into the mucosa laminar propria of the airway. It has been 
known that some allergens with protease character penetrate mucosa or dendritic cells 
directly sample the inhaled antigens from the respiratory lumen (226). Here we found that 
CD23 is capable of transport of IgE and the immune complex across polarized human 
airway epithelial monolayer.  
CD23 expression has been shown in many immune cells. In this study, we have 
















Figure 2.7 Immune complex transported by CD23 in polarized Calu-3 cells facilitated mast cell degranulation.  
A. Effect of transcytosis of the immune complex on degranulation of mast cells. Calu-3 cells (1 × 105/ml) were grown on 0.4 
µm pore size inserts. The cells were allowed to get polarized. The immune complexes were made by incubating chimeric anti-
NP IgE with NP-BSA. Supernatants from the basolateral chamber containing mast cell LAD2 (1 X 105/ml) were sampled 3 hr 
later after addition of IgE, NP-BSA (Ag), immune complex (IC) to the apical chamber. In a 96 well plate, the transcytosed 
immune complexes were also incubated with LAD2 cells that were primed with or with ut NP specific IgE or non specific IgE 
(right panel). The tryptase (left panel) or β-hexosaminidase (middle panel) activity in the supernatant was measured as 
described in Materials and Methods. Medium was used as a negative control (mock). LAD2 mast cells (1 X 105/ml) that were 
directly incubated with the immune complex were used as a positive control (IC control).   
B. Representative immunofluorecence staining of LAD2 mast cell for tryptase expr ssion during degranulation. LAD2 cells 
from the above experiments (A) were fixed and permeabilized in 0.1% Triton X-100. Subsequently, th  cells were incubated 
with affinity-purified mouse anti-tryptase mAb (green), followed by staining with an Alexa flour 488-conjugated rabbit anti-
mouse Ab. The nucleus was stained with DAPI (blue). Experimental conditions are displayed in the top. 
C. Schematic description of mast cell degranulation by transcytosed immune complex in a transcytosis model. IgE from 
mucosal plasma cells or from the blood are transported by CD23 into the airway lumen. Upon meeting with airborne allergens, 
the immune complexes (IC) are formed. CD23 acts as a bidirectional IgE transporter and facilitates apical (luminal)-to-basal 
transport of IgE-allergen complexes. At the subepithelial side, airborne allergens or the immune complexes engage with FcεRI 




cell lines derived from the nose, trachea, and lung (Fig. 2.1). We were not able to obtain 
respiratory biopsy samples and therefore examined a model tissue as a measure of airway 
CD23 expression. The association between CD23 and IgE was also demonstrated in a 
CD23 dependent IgE uptake assay in the human airway Calu-3 cells proving that CD23 is 
structurally intact in this cell type. Therefore, our results support and extend th  previous 
finding that CD23 is constitutively expressed in human intestinal epithelial cls (140, 
145). We further found that human airway epithelial cells expressed CD23b, but not 
CD23a, mRNA (Fig. 2.1). The absence of CD23a protein expression by airway epithelial 
cells may indicate lack of constitutive expression, but it may also be due to the absence of 
a required growth factor in cell culture media. Our study does not rule out expression of 
CD23a in intact tissues in vivo. Clearly, in situ hybridization studies are necessary for 
conclusive evidence regarding CD23 isoforms expressed by specific cell types in vivo. 
The expression of isoform specific CD23 mRNA in human intestinal epithelial cells 
remains controversial (144, 145). It is possible that cells grown in non-polarized or 
polarized conditions might affect the expression of CD23 isoform in polarized epithelial 
cells (143). Interestingly, intracellular expression of CD23 in airway epithelial cells 
suggests CD23 functions as an intracellular receptor for IgE.  
CD23 transports human IgE in polarized airway epithelial monolayer. The 
function of CD23 has been most extensively studied on B cells, where it is involved in 
IgE-mediated antigen capture and facilitated presentation to T cells or regulation of IgE 
homeostasis (77, 130). There is a paucity of information on the link between engagement 
of CD23 on the airway epithelial cells and the functional outcome. In airway epithelial 




suggesting that IgE may be transported in both directions across the epithelium (Fig. 
2.3A). In fact, we demonstrated that human lung epithelial cell Calu-3 cell line 
transcytosed the exogenously applied IgE which occurred in both apical-to-basal and 
basal-to-apical directions (Fig. 2.3C). Most importantly, human IgE was transported 
bidirectionally at concentrations representing at both physiological and allergy conditions 
(Fig. 2.3D). In our studies, IgE was clearly released after transcytosis although we did not 
determine the relative quantity of free IgE against that which remains associated with its 
receptor. To confirm the specific transport, we conducted additional experiments usi g 
either soluble CD23 or CD23 specific Ab. We showed that either of them was able to 
significantly decrease IgE transport across the Calu-3 cell monolayer (Fig. 2.3). These 
results, taken together with the temperature sensitivity of IgE transport, provide evidence 
that the transepithelial transport of IgE is mediated by the CD23 expressed in th  airway 
epithelial cells. The IgE transport in airway epithelial cells was partially sensitive to 
bafilomycin, suggesting the transcytosis occurs also through endosome. Both IgA and 
IgG transcytosis by the polymeric immunoglobulin receptor (pIgR) and FcRn have also 
been shown to be sensitive to agents that interfere with pH gradients (150, 177). In 
contrast to FcRn-mediated IgG and pIgR-mediated IgA transcytosis, it remains unclear 
how CD23 releases IgE at cell surface after transcytosis. Although the intracellul r 
trafficking mechanism of CD23 has just begun to be explored, the similar ability of CD23 
and FcRn to mediate bidirectional transcytosis suggests possible similarities in their 
transport mechanism. 
      CD23 transports IgE-derived immune complex across the airway epithelial 




when a host inhales allergen, it may combine with the allergen specific IgE present on the 
lumen or cell surface to form immune complexes and it can then be transcytosed across 
the airway epithelial barrier. To mimic the natural condition, we performed the 
transcytosis of immune complex from the apical to basolateral direction and found that 
Calu-3 monolayer efficiently transcytosed the immune complex, but not antigen alon 
(Figs. 2.4A & 2.4B). In confirmation of the specificity of CD23 in transepithelial antigen 
transport, sCD23 or CD23 specific Ab blocked antigen uptake and transport of antigen in 
a concentration-dependent manner (Fig. 2.4). Furthermore, primary human tissues could 
also transcytose IgE or immune complex (Fig. 2.6). This is, however, not surprising given 
the fact that CD23 has been described previously as mediating endocytosis of immune 
complex in B cells (119, 213, 227). However, several issues should be noticed. First, in 
our experiment, an intact antigen was detected in the transport of the immune complex. 
This is consistent with the previous finding that CD23 mediated transepithelial 
transcytosis of the immune complex diverts antigen from lysosomal degradation in 
intestinal epithelial cells (145, 228). It is possible that by protecting antigen from 
degradation, CD23-mediated transcytosis of the immune complex may increase quantity 
of antigen delivered across the airway epithelium into the body. Second, the transport of 
the immune complex in the apical to basolateral direction was much more efficient than 
that of IgE alone since we were able to easily detect the immune complex in our assay. 
The rationale for this discrepancy may be due to the sensitivity of detection methods for 
NP antigens. Alternatively, immune complex bound to CD23 airway epithelial cells may 
cross-link CD23 molecule, initiate signaling cascade, and subsequently result in enhanced 




already found that the immune complexes on the intestinal epithelial monolayers 
preferentially activate MAPK signaling pathway and subsequent release of ch mokines 
IL-8 and CCL20 (146, 147). Although the exact mechanisms of this antigen transport 
system need to be further investigated, our results provide convincing evidence that 
human airway cell lines and primary airway tissue can transcytose IgE-derive  immune 
complex, which is mediated by IgE and CD23. Therefore, CD23 can function as an 
antigen-sampling mechanism by transporting intact allergen-IgE complexes across 
human airway epithelia. 
What might be the clinical implication and significance of CD23 mediated IgE 
and immune complex transport in human airway epithelial cells? Expression of CD23 
and IgE level is enhanced in asthma patients (156, 165). CD23 is involved in regulating 
IgE synthesis in B cells (125), developing extrinsic allergic alveolitis in alveolar 
macrophages (164), and reacting to stimulations in airway smooth muscle cells (161). 
Our study enlightens the role of CD23 in transepithelial transport of IgE and immune 
complex which may have significant role in the development of airway allergic 
inflammation. We speculate that this may be an important step in the amplification of 
adaptive immune responses to allergen ingestion or may be a critical step in th  initiation 
of a local late-phase airway inflammatory response. Since IL-4 is elevated in all allergic 
conditions, our results have clearly demonstrated that airway epithelial cell CD23b 
mRNA appeared to be IL-4 dependently up-regulated. The increased expression of 
induced CD23 is most likely due to activation of the IL-4 enhancer element on the CD23 
gene (219). More importantly, exposure of IL-4 up-regulated CD23 expression and 




Calu-3 monolayer (Fig. 2.5).  It should be noted IL-4 treatment did not lead to the 
transport of immune complex at 4 ºC, suggesting that IL-4 influences IgE transpo t by 
stimulating expression of CD23 rather than by inducing nonspecific increases in 
permeability of the epithelial monolayer. Although we did not obtain respiratory bipsy 
samples from patients with IgE-mediated asthmatic allergies, IgE presenc  in human 
airway secretions of individuals with asthma has been documented. It is very likely that 
CD23 might enhance transport function on airway epithelial cells in asthmatics. Our 
discovery was in agreement with findings from IL-4 enhanced IgE and immune complex 
transcytosis in the intestinal epithelial cells (138, 144, 145). Transport of the immune 
complex may lead to several immunological consequences in shaping the airway allergy.
First, binding to IgE/CD23 protects antigen from degradation during transepithelial 
transport resulting in large quantities of allergens gaining access to the lamina propria in 
a short period. This allergen or immune complexes is available to activate mast cells, 
basophiles, through cross linking FcεRI and initiate the hypersensitivity reaction. We 
have shown that IgE-Ag complexes that were transcytosed across human airway 
epithelial cells triggered the degranulation of mast cells (Fig. 2.7A+2.7B). Therefor , it is 
conceivable that the degranulation subsequently leads to the release of various 
inflammatory and lipid mediators contributing to airway perturbation and 
hypersensitivity reactions. Second, the transport of the immune complexes may be 
accompanied by cytokine release from immune cells in the mucosa, which may enhance 
the expression of CD23 on the airway epithelial cell layer. Therefore, each exposure to 
immune complex could potentially enhance CD23 expression on the epithelial cell layer 




delivered to antigen-presenting cells such as dendritic cells or basophiles for presentation 
to T cells. These cells can use FcεRI receptor for capturing IgE complexed antigen. More 
interestingly, the sensitization can increase uptake of specific antigen via a endosomal 
transcellular pathway across tracheal and jejunal epithelium (229, 230). Further, in vitro-
formed IgE immune complexes, when administered through the airways, are more potent 
than antigen alone in inducing airway inflammatory responses in mice previously 
sensitized with the antigen (231). However, these studies did not reveal the CD23 
dependent transport of the immune complex on airway epithelial cells. Therefore, our 
study may reveal a novel antigen transport or capture mechanism leading to an allergic 
response to inhaled allergens in an atopy individual.  
      Although CD23 expression has been noted previously in intestinal epithelial cells, 
to our knowledge, this is the first study to identify that CD23 expressed in human airwy
epithelial cells is a receptor involved in the binding and bidirectional transport of IgE 
across polarized airway epithelial monolayers. Taken together, the results obtained in this 
study demonstrate that CD23, expressed on human airway epithelial cells, acts as  bi-
directional IgE transporter, which is regulated by IL-4. Both directions fit well ith the 
model that IgE produced within the body is transported to the apical membrane of airway 
epithelial cells and released into the lumen, resulting in binding inhaled allergens. It is 
possible that free allergen can attach to IgE-CD23 complex too. CD23 facilitates apical-
to basal transcytosis of functional IgE/antigen complexes, which are capable of triggering 
underlying effector cells, such as mast cells for degranulation (Fig. 2.7C). Such activation 
may provide feedback to the airway epithelium to signal cytokine or chemokine release 




airway mucosa. We, therefore, speculate that CD23 is a critical receptor in the initiation 
of allergic responses in human airway allergic inflammation. Besides unraveli g these 
basic mechanisms of CD23-mediated IgE and immune complex transport in humans, this 
study also suggests that blocking CD23-mediated IgE transport is a potentially important 





















CHAPTER 3: CD23 MEDIATED TRANSCYTOSIS OF IGE AND IMMUNE 




       IgE is one of the major contributing factors for the development of allergic 
diseases and its exact role in airway mucosal secretions remains elusive. The presence of 
IgE in mast cells and basophils cross linked by the allergen and trigger the releasof 
variety of inflammatory mediators associated with allergic inflammtion. We have 
previously showed that human CD23 is capable of transporting IgE and immune complex 
across the polarized respiratory epithelial cells, implying CD23 may play a critical role in 
initiating and contributing to the airway allergic inflammation. To verify thisin a mouse 
model, we at first showed that mouse CD23 was expressed in airway epithelial cells. 
Sensitization of Balb/c mice with allergen ovalbumin (OVA) augmented CD23 
expression in airway epithelial cells. Transcytosis of OVA-specific IgE across mouse 
airway was demonstrated bidirectionally from the apical to basolateral or the basolateral 
to apical and exhibited in a time- and dose-dependent manner. The OVA was also 
detected by transcytosis across airway barrier when mice were intranassally inoculated 
with OVA immune complex. The CD23 mediated specific transport of either IgE or 
immune complexes was further verified in a CD23 knockout mice. A further experiment 
for showing the roles of epithelial CD23 in regulating the airway allergic inflammation 
by transporting allergens in an immune complex form is being investgated in an OVA-





Allergic diseases are one of the most common immunological disorders which 
include allergic asthma, allergic rhinitis, food allergy, atopic dermatitis, and anaphylaxis 
affecting approximately 25% people in the developed world (202). The airway allergic 
inflammation is commonly characterized by presence of eosinophils and CD4+ T cells
(232, 233). Allergen inhalations into patients with atopic asthma activate the Th2 type 
CD4+ T cells and enhance cytokine expression of IL-4, IL-5, granulocyte-macrophage 
colony-stimulating factor (GM-CSF) and eosinophil accumulation (233). These Th2 cells 
play an important role in the pathogenesis of allergic asthma (202). Airway inflmmation 
is predominantly associated with IgE and characterized by the presence of allergen 
specific IgE in the airway tract (1, 234), although IgE independent allergy has also been 
documented (235). Local production of allergen specific IgE by class switch in B cells 
leads to IgE appearance in the airway secretion (236, 237). Allergen specific IgE binds 
high affinity receptor for IgE (FcεRI) on the mast cells, eosinophils and basophils and 
plays a very important role in the pathogenesis of airway allergic inflammation. Allergen 
cross-linking of surface IgE leads to cell degranulation and the release of various allergic 
mediators (1, 202, 237). These include proteases, biogenic amines, prostaglandins, 
leukotrienes, etc. and acts on the local tissue like epithelial and smooth muscle cell  
(202). In order for inhaled allergens to interact with immune cells, allergens have to 
access and activate the immune cells in the lamina propria of the airway tract. However, 
the epithelial cells lining the airway form a mucosal barrier by forming tight junctions 
between the adjacent cells. Hence macromolecules, like inhaled allergens, have to first 




CD23, a receptor for IgE is the only Fc receptor that belongs to a C-type lectin 
family consisting of three lectin head domain in the C-terminal that can bind to IgE
followed by a triple α−helical coiled-coil stalk region, transmembrane and short 
cytoplasmic tail domain (1). CD23 binds IgE with a dual affinity, a low affinity (Ka ≈ 10
6 
-107 M-1) in the monomeric state and high affinity to IgE (Ka ≈ 10
8 -109 M-1) in a trimeric 
form (1, 63, 64). CD23 is susceptible to proteolytic cleavage by enzymes like ADAM10 
and house dust mite protease der p1 at the stalk region, which is responsible for releasing 
various soluble CD23 (104, 105, 109). Soluble CD23 has multiple functions involved in 
IgE homeostasis and various cytokine like activities (12, 63, 64). CD23 exists as two 
isoforms, CD23a and CD23b. They have different transcription initiation sites and differ 
only in the N-terminal cytoplasmic region by 6-7 amino acids (76, 77). In humans, the 
isoform CD23a is expressed only in the B lymphocytes while CD23b is expressed in 
variety of cells like monocytes, eosinophils, langerhans, respiratory and intestinal 
epithelial cells (77, 144, 145, 238). In mice, CD23 is expressed in B cells, follicular 
dendritic cells, and intestinal epithelial cells (58, 80, 81, 140-142). CD23 functions in 
enhancing IgE-specific antigen processing and presentation in the form of IgE/anti en 
complexes (117-120), regulation of IgE production (63, 64, 125, 126, 128), and 
influencing cell differentiation, survival and growth of B- and T-cells and myeloid 
precursors (131, 133-135). Several studies showed that human and murine intestinal 
epithelial cells express CD23 receptors and are capable of transporting either IgE or IgE-
allergen immune complex across the polarized epithelial cells (140-142, 144, 145).   
Recently, we showed that human respiratory epithelial cells express CD23 and IL-




complexes (238). Furthermore, CD23 enhanced intestinal transepithelial antigen transport 
in a sensitized allergic rat and mouse model (140-142). All of these experiments stro gly 
showed a role for CD23 in aiding allergy by enhanced IgE or antigen transport across the 
polarized epithelial cells lining the mucosal surfaces.  However, the expression of CD23 
and its function in murine respiratory tract remain elusive. Here we showed that CD23 
was expressed in mouse respiratory tract and was capable of transporting mouse IgE or 
IgE-derived immune complexes.  
  
MATERIALS AND METHODS 
Antibodies, mice, cells and reagents. The murine lung epithelial cell line LA4 was 
purchased from the American Type Culture Collection (ATCC, Manassas, VA). The cells 
were cultured in Ham's F12K complete medium containing 15 % FBS, 1% L-glutamine, 
non-essential amino acids, 100 U/ml penicillin and 100 µg/ml streptomycin. The cells 
were grown in a humidified atmosphere at 37ºC containing 5% CO2.  hicken ovalbumin 
(OVA, Grade V), was purchased from Sigma Aldrich (St. Louis, MO). The anti-murine 
CD23 antibody-secreting hybridoma B3B4, rabbit anti-murine CD23 antibody, CD23 
knockout (KO) mouse on a Balb/c background were  kind gifts from Dr. Daniel Conrad 
(Virginia Commonwealth University School of Medicine, VA). Six- to eight-week-old 
inbred female Balb/c mice were purchased from the National Cancer Institute (Frederick, 
MD). 
Mouse anti-OVA IgE was purchased from Bio X-cell (West Lebanon, NH). 
Rabbit anti-mouse IgE-HRP, normal rabbit IgG, mouse anti-chicken OVA mAb and 




Louis, Mo). Mouse anti-β-tubulin antibody was purchased from Developmental Studies 
Hybridoma Bank (The University of Iowa, Iowa City, IA). Rabbit anti-mouse IgG HRP 
conjugated antibody was obtained from Pierce (Rockford, IL). FITC- conjugated 
polyclonal goat anti-mouse IgE and normal goat anti-mouse IgE antibody were obtained 
from Novus Biologicals (Littleton, CO).  Alexa fluor 555 conjugated Goat anti-rbbit or 
anti-mouse IgG and Alexa fluor 633-conjugated goat anti-rabbit IgG were purchased 
from Invitrogen.  HRP conjugated bovine anti-goat IgG antibody was purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA).  FITC conjugated rat anti-mouse B3B4 
mAb and rat anti-mouse CD16/CD32 antibody were obtained from BD Pharmingen (San 
Diego, CA).  APC conjugated rat anti-mouse CD45R (B220) and FITC conjugated 
isotype rat IgG2a antibody were obtained from Caltag laboratories. Biotin-labelled mouse 
anti-OVA IgE antibody was generated by EZ-Link Sulfo-NHS-LC-Biotin (Pierce, 
Rockford, IL) following manufacturer’s instruction. Recombinant murine IL-4 was from 
R&D Systems (Minneapolis, MN). Proteinase inhibitor cocktail was purchased from 
Calbiochem (San Diego, CA).  
 
RT-PCR. Semi-quantitative RT-PCR was performed on total RNA extracted from lung 
epithelial cell line LA4 as previously described (238). Total RNA was isolated from 2 x 
106/ml LA4 cells either mock stimulated or stimulated with murine IL-4 (20 ng/ml) using 
TRIzol reagents (Invitrogen) according to the manufacturer’s instructions.  O e-step RT-
PCR kit (Qiagen) was used to perform semi-quantitative RT-PCR. Negativ control was 
performed without addition of RNA template.  Primers used for amplification of murine 




previously. Primers used for the amplification of gylceraldehyde-3-phosphate 
dehydrogenase (GAPDH) were GAPDH-F 5’-ACC CAG AAG ACT GTG GAT GG -3’ 
and GAPDH-R 5’-CAC ATT GGG GGT AGG AAC AC-3’. Amplification of CD23 
mRNA and GAPDH were performed with 450 ng of total RNA in 20-µl volume. One step 
RT-PCR amplification cycle consisted of reverse transcription at 50°C for 30 min, initial 
PCR activation at 95°C for 15 min, followed by PCR cycle of denaturation at 94°C for 1 
min, annealing at 60°C for 1 min, extension at 72°C for 2 min for 40 cycles and final 
extension at 72°C for 10 min. Annealing temperature for GAPDH was 55°C for 1 min and 
the rest of the amplification conditions are same. RT-PCR products were analyzed by 
resolving on 1.5 % agarose gel and DNA visualized by ethidium bromide staining. Semi-
quantitative analysis of CD23 band intensities of RT-PCR products normalized to GAPDH 
values were analyzed by densitometry using Adobe Photoshop.  
 
Genotyping of CD23 knockout (KO) mice. Genotyping of the CD23KO mice on Balb/c 
background was performed with genomic DNA isolated from mouse tail using Puregene 
DNA isolation kit (Qiagen) following manufacturer’s protocol. Primers used for genotyping 
were previously described (239). PCR amplification cycle consisted of initialPCR 
activation at 94°C for 3 min, followed by PCR cycle of denaturation at 94°C for 30 sec, 
annealing at 63°C for 1 min, extension at 72°C for 2 min for 35 cycles and final extension at 
72°C for 10 min. PCR products were analyzed by resolving on 1.5 % agarose gel and DNA 





SDS-PAGE and Western blotting. SDS-PAGE and Western blot were performed as 
described previously (238). Protein concentrations of cell lysates were determin d by 
Bradford method. The cell lysates were resolved on 12% SDS-PAGE gel electrophoresis 
under reducing conditions. Proteins were transferred onto a nitrocellulose membran  
(Schleicher & Schuell) and the membrane was blocked with 5% skim milk in PBS. The 
membranes were probed separately with rat anti-murine CD23 mAb B3B4 or murine 
anti-β-tubulin antibody for 1 hr at room temperature or overnight at 4°C and then 
incubated with HRP-conjugated rabbit anti mouse antibody. All blocking, incubation, and 
washing procedures were performed in PBST solution (PBS and 0.05% Tween 20). 
Proteins were visualized using ECL method (Pierce).  
 
Preparation of primary bronchoalveolar and tracheal epithelial cells. The 
bronchoalveolar epithelial cells were isolated as previously described (240). The tracheal 
epithelial cells were isolated by following the procedures as described previously (241). 
Briefly, the bronchoalveolar and tracheal epithelial cells were isolated by enzymatic 
digestion of lung with dispase (2.4 units/ml in DMEM) and trachea with pronase (1.5 
mg/ml in Ham's F-12 pen-strep) and the remaining procedures were  performed as 
described previously (240, 241).  
 
Immunohistochemistry. Immunohistochemistry was performed as previously described 
(238). Mouse lung and trachea were inflated and embedded with OCT medium and 
cryosectioned at 5 µM thickness. Serial cryosections of the frozen tissue were fixed and 




for 1 hr at room temperature. Tissue sections were incubated with affinity purified rabbit 
anti-murine CD23 antibody, FITC-conjugated pan-cytokeratin antibody, FITC-
conjugated goat-anti mouse IgE antibody or mouse anti-chicken OVA antibody in a 
humidified chamber overnight at 4°C followed by alexa-fluor 555-conjugated goat anti 
mouse antibody or alexa fluor 555- or 633-conjugated goat anti-rabbit antibody. All 
incubations were performed with 3% normal goat serum and finally nuclei were 
counterstained with DAPI (0.5 g/ml, Molecular Probes) in PBS.  Negative controls were 
performed by incubating the isotype-matched mouse or normal rabbit IgG as primry 
antibody. Cover slips were mounted on the tissue sections with Prolong antifade reagent
(Molecular probes, Invitrogen) and visualized and images were taken using Zeiss 
LSM510 laser scanning confocal microscope (Zeiss Microimaging Inc., NY). Images 
were processed by Zen 2007 software and Adobe Photoshop.  
 
In-vivo transcytosis and enzyme-linked immunosorbent assay (ELISA). The Ova-
specific IgE and chicken OVA were measured with ELISA. ELISA plates (Nunc) were 
coated with rabbit anti chicken OVA antibody (10 µg/ml) for detecting OVA or coated 
with chicken OVA (10 µg/ml) for detecting OVA-specific IgE overnight at 4ºC. Plates 
were then washed three times with PBST (0.05% tween- 20 in PBS) and blocked with 10 
% FBS in PBS for 1 hr at room temperature. In-vivo transcytosis was performed with a 
set of WT and CD23KO mice on Balb/c background. Mouse anti-OVA IgE (50 µg/40µl) 
in PBS was given either intranasally or intraperitoneally and serum samples or 
bronchoalveolar lavage (BAL) fluid were collected 4, 8 or 24 hr later, respectively.  




µl) in PBS for 30 min at room temperature or chicken OVA antigen alone (10 µg/4  µl) 
in PBS was given intranasally and 8 hr later serum samples were collected.  The 
transcytosed serum or BAL samples, IgE or OVA standards diluted in 10% FBS in PBS 
were incubated for 2 hr at room temperature. Goat anti-mouse IgE (1:1000, Novus 
Biologicals) and HRP-conjugated bovine anti goat antibody (1:10,000, Santa cruz) were 
used for detection of mouse IgE. For detection of chicken ovalbumin, biotinylated mouse 
anti-OVA IgE (1:10,000) and HRP-conjugated Streptavidin (1:250, BD) were used. Total 
IgE was calculated by using OptEIA mouse IgE ELISA kit following manufactrer’s 
protocol (BD). A colorimetric assay was done with tetra methyl benzidine (TMB) and 
hydrogen peroxide and a Victor III microplate reader (Perkin Elmer).  
 
Bone-marrow chimera model development. CD23KO mice on Balb/c background were 
irradiated with 800 Rads and repopulated with 5 x 106 WT bone-marrow derived cells 
given intravenously via tail vein. Repopulation with WT cells in the reconstituted mice 
was estimated by analyzing CD23 expression in the B cells,   total T cells in sp ee  or B 
cells in bone marrow by flow cytometry as above described.  
 
Flow cytometry. Surface expression of CD23 on the fixed splenic B cells isolated from 
either Balb/c WT or CD23KO mice were analyzed by flow cytometry. Presence of 
CD11c and Siglec-F +/- cells in the brochoalveolar lavage obtained from OVA sensitized 
and challenged Balb/c WT or chimeric CD23KO mice were also analyzed by flow 
cytometry. For staining, 1 X 106 spleen B cells or 1 X 105 BAL cells (pooled from 5 




blocking mouse Fc binding with mAb to CD16–CD32 on ice for 30 min. The cell 
suspensions were respectively incubated with murine FITC conjugated anti-CD23 B3B4, 
FITC-conjugated rat IgG2a, APC-Cy7-conjugated anti-B220 antibody, and APC-Cy7-
conjugated rat IgG2a antibody, FITC hamster anti mouse CD11c, PE rat anti mouse 
siglec-F, FITC hamster IgG1, PE rat IgG2a for 30 min at 4°C, then washed and analyzed 
using a FACSAria II and the software FlowJo.  
 
OVA sensitization and challenge: The mice were sensitized with chicken ovalbumin by 
mixing with alum and given intraperitoneally. The sensitization consists of 100 µg OVA 
mixed with 4 mg Alum given on day 0 and 100 µg ova diluted in PBS on day 7 and 14. 
In some experiments, the mice were sensitized for single time with 100 µg OVA mixed 
with 4 mg Alum given on day 0. On day 21, the mice were challenged with 1% aerosol 
OVA and 24 hr later, the mice were sacrificed to collect BAL fluid, serum, and lung 
tissue for histopathology. BAL fluid was subjected to cytospin and stained with modified 
wright-giemsa stain (Sigma) for counting differential cells.  
 
Statistics. The statistical difference between groups was tested by Student t test. A P 
value of less than .05 was considered significant. Data are expressed as mean ± SD. 
 
RESULTS 
Mouse respiratory epithelial cells express CD23. Epithelial cells isolated from mouse 
lung, trachea, and lung epithelial cell line LA4 were used in the analysis of mouse CD23 




(242). The lung and tracheal airway epithelial cells isolated from naive mice expr ssed a 
protein band (49 kDa) identical to that of spleen positive control (Figure 3.1A). CHO cell 
lysate was included as a negative control (Figure 3.1A). Similar to the human CD23,
mouse CD23 also exists in two isoforms, CD23a and CD23b (76, 142). To verify which 
isoform is expressed, the analysis of mouse CD23 mRNA expression by RT-PCR in 
mouse lung epithelial cell line LA4 was performed. Results showed that CD23b, but not 
CD23a mRNA, was detected (Figure 3.1B). The PCR products were further sequenced to 
confirm the specificity of CD23b mRNA by sequence analysis. The expression of CD23b 
mRNA in mouse lung epithelial cells is in agreenment with CD23 expression pattern in 
human airway epithelial cells (238). Since airway allergic inflammation is mediated by 
Th2 cytokine IL-4 and IL-13, for example, IL-4 has been shown to enhance the 
expression of CD23 in B cells, respiratory and intestinal epithelial cells (141, 219, 238). 
Mouse lung epithelial cells LA4 treated with IL-4 resulted in the enhanced expression of 
CD23b specific mRNA (Figure 3.1B, lane 3, top panel). Mouse intestinal epithelial cel s 
expressed CD23b mRNA lacking exon 5 (CD23b∆5) and binds to the IgE with high 
affinity (142, 143).  However, we failed to detect the expression of CD23b∆5 mRNA in 
mouse lung epithelial cells LA4 (Figure 3.1B, middle panel). Immunohistochemistry 
analysis of positive control, spleen, revealed the expression of CD23, but not for the 
normal rabbit IgG (Figure 3.1C) confirming the specificity of CD23 antibody used in this 
experiment. Further, CD23 was expressed in the naive lung and trachea; however, CD23 
staining was negative when normal rabbit IgG was used (Figure 3.1D & 3.1E).  
Cytokeratin staining was used as a specific marker for lung and tracheal epithelial cells. 












Figure 3.1 Mouse respiratory epithelial cells express CD23.  
(A) CD23 protein was expressed by mouse respiratory tracheal and lung epithelial cells. 
The cell 
lysates (50 µg) from naïve tracheal epithelial cells (lane 1), naïve lung epithelial c lls 
(lane 2), CHO cells (lane 3) and spleen (lane 4) were gel electrophoresed and separated 
on 12 % SDS-PAGE gel under reducing condition. The separated proteins were 
transferred on nitrocellulose membrane, blocked and blotted with rat anti mouse CD23 
antibody B3B4. The blots were washed and further incubated with HRP conjugated 
rabbit anti rat IgG antibody and the protein bands were visualized by ECL method. The 
arrow indicates the location of mouse CD23 and β-tubulin. 
 (B) CD23b specific mRNA but not CD23a, isoform was expressed in mouse lung 
epithelial cells LA4. TRIzol reagent was used to extract total RNA from untreated lung 
epithelial cells LA4 (lane 2), IL4 (20 ng/ml) treated LA4 cells (lane 3), negative control 
without the addition of mRNA template (lane 1).  RT-PCR was performed to amplify 
CD23a, CD23b, CD23b∆5 and GAPDH using gene specific primers as described in 
Materials and Methods. Amplified PCR products were electrophoresed in 1.5% agarose 
gels and stained with ethidium bromide. The arrow indicates amplification products for 
mouse CD23 and GAPDH. Densitometry analysis of CD23b band intensities normalized 
to GAPDH was presented in the bottom panel. *P<0.05.   
(C-E) Immunohistochemistry staining of mouse spleen, lung and trachea. The naive 
mouse spleen, lung and tracheal tissue were mounted in OCT medium and cryosectioned 
at 5 µM thickness. The frozen tissue sections were fixed and permeabilized with ice-cold 
acetone and blocked with 10% normal goat serum. For the positive control, spleen 
sections were stained. The sections were incubated with rabbit anti CD23 antibody or 
normal rabbit IgG, followed by staining with alexa flour 555-conjugated goat anti rabbit 
antibody and FITC conjugated anti cytokeratin antibody. The nucleus was stained with 
DAPI and imaged using LSM510 confocal microscope. Samples were visualized under 













colocolized and merged (yellow), suggesting CD23 specific expression in epithelial cells.  
 
Characterization of OVA-sensitized mice. Wild-type mice were sensitized with OVA or 
left untreated, followed by challenge with 1 % aerosol OVA in PBS and chara terized for 
the development of allergy. Results from PAS (Periodic Acid Schiff) staining showed the 
presence of PAS-positive mucin staining in epithelial cells only from the sensitiz d mice 
in comparison with the epithelial cells from naive animals (Figure 3.2A).  TotalIgE 
detected in the serum was significantly higher in the sensitized mice compared with the 
naive mice; in addition, ova specific IgE was detected in the serum of sensitized mice but 
not in that of the naive mice (Figure 3.2B & 3.2C).  Bronchoalveolar lavage (BAL) fluids 
were collected either 24 or 72 hr later from OVA sensitized or naive mice which were 
aerosolly challenged with 1% OVA. At 24 hr time point, significant amount of total IgE, 
OVA specific IgE and cytokine IL-4 were detected only in the OVA sensitized and 
challenged mice, when compared to the non-sensitized and OVA challenged mice (Figur
3.2D, 3.2E & 3.2F). 72 hr later after challenge, BAL fluid contains significantly higher 
amount of total leukocytes, eosinophils, total and OVA specific IgE in the OVA 
sensitized and challenged mice, when compared to the non-sensitized and OVA 
challenged mice (Figure 3.2G, 3.2H, 3.2I & 3.2J).  OVA specific IgE was completely 
absent in the non-sensitized and OVA challenged mice. Taken together, sensitization of 
mice with OVA leads to the development of allergic inflammation in a mouse model.  
 
CD23 expression is enhanced in the sensitized mice. Balb/c mice were left untreated or 













Figure 3.2 Characterization of OVA-sensitized mice.  
(A). PAS staining of sensitized and naive lung sections. Balb/C mice were sensitized with 
ova or left untreated and challenged with 1% aerosol ova. Lung tissue was fixed with 10 
% neutral buffered formalin and paraffin embedded sections at 5 µM thickness, followed 
by deparaffinization and hydration. The sections were oxidized with periodic aci 
solution and stained with Schiff reagent.  Samples were visualized and imaged with 40x 
oil immersion microscope.  
(B)-(C). Detection of total and ova-specific IgE. Serum was collected from the sensitiz d 
and naïve mice  
21 days after the first immunization with ova and alum. Serum were tested and measured 
for total and ova-specific IgE by ELISA.  
(D)-(F). Detection of total IgE , ova-specific IgE and IL4 in BAL. Mice were sensitized 
with ova or left untreated. On day 21, the mice were challenged with 1% aerosol ova and 
24 hours later, mice were sacrificed with avertin and BAL fluid were collected. Total 
IgE, Ova-specific IgE and IL4 were measured in the BAL fluid by ELISA. 
(G)-(J). Detection of total leukocytes, eosinophils, total IgE, ova-specific IgE and IL4 in 
BAL. Mice were sensitized with ova or left untreated. On day 21, the mice were 
challenged with 1% aerosol ova and 72 hours later, mice were sacrificed with avertin nd 
BAL fluid were collected. BAL fluids were cytospin centrifuged followed by staining 
with modified wright-giemsa stain and total leukocytes and eosinophils were counted. 

















with the elevated level of IL-4, IL-13, and allergen specific IgE. The IL-4 enhances the 
expression of CD23 in B cells, monocytes, intestinal and respiratory epithelial cells (105, 
141, 219, 238). To verify this enhancement in mouse airway, the lung and tracheal airway 
epithelial cells freshly isolated from the sensitized and naive mice were blott d for the 
CD23. Results from the western blot showed that CD23 protein was significantly up-
regulated in the lung and tracheal epithelial cells from the OVA sensitized, but not the 
naive mice (Figure 3.3A & 3.3B). Immunohistochemistry analysis of the lung and tr chea 
in the sensitized mice also revealed that  expression of the CD23 protein (red) co-
localized with epithelial cell marker cytokeratin (green), which showed by a yellow color 
(Figure 3.3C).  
 
Genotyping and characterization of CD23 KO mice. CD23KO mice on Balb/c 
background were received from Dr. Daniel Conrad (Virginia Commonwealth University, 
VA). Genotyping of the CD23KO mice was performed by PCR amplifications. In 
previous study, two specific primer pairs were designed to differentiate the wild-type and 
CD23 KO mouse (239). The genomic DNA isolated from mouse tail was used as a 
template. PCR reaction amplified a 1033 bp DNA fragment indicative of wild-type CD23 
allele, whereas 1104-bp DNA band represented the genotype from CD23 KO mice 
(Figure 3.4A). Surface expression of the CD23 in mouse spleen B cells was further 
analyzed by flow cytometry. CD23-positive B cells are defined as B220+CD23+. They 
were expressed only in the wild-type splenocytes and but not in B cells from CD23KO 







Figure 3.3 Sensitization augments CD23 expression. 
(A)-(B). Mice were sensitized with ova or left untreated. Epithelial cells of lung and 
trachea from the naive and sensitized mice were isolated as described in Materials nd 
methods. The cell lysate (50 µg) from naïve trachea or lung (lanes 1 &2) and sensitized 
trachea or lung (lanes 3 & 4) were gel electrophoresed and separated on 12 % SDS-
PAGE gel under reducing condition. The separated proteins were transferred on 
nitrocellulose membrane, blocked and blotted with rat anti mouse CD23 antibody B3B4. 
The blots were washed and further incubated with HRP conjugated rabbit anti ratIgG
antibody and the protein bands were visualized by ECL method. The arrow indicates the 
location of mouse CD23 and β-tubulin. Densitometry analysis of CD23 band intensities 
normalized to the β-tubulin band intensities were presented in the bottom panel. *P<0.05.   
(C). Immunohistochemistry staining of CD23 expression.  The sensitized mouse lung and 
tracheal tissue were mounted in OCT medium and cryosectioned at 5 µM hickness. The 
frozen tissue sections were fixed and permeabilized with ice-cold acetone and blocked 
with 10% normal goat serum. The sections were incubated with rabbit anti CD23 
antibody followed by staining with alexa flour 555-conjugated goat anti rabbit antibody 
and FITC conjugated anti cytokeratin antibody. The nucleus was stained with DAPI and 
imaged using LSM510 confocal microscope. Samples were visualized under same 











Figure 3.4 Genotyping and characterization of CD23 KO mice. 
(A). Genotyping of CD23KO mice. Genomic DNA was isolated from the tail of wildtype 
and CD23KO mice. PCR was performed with Wild type and CD23KO mice genomic 
DNA using either wild type or Knockout primers as described in materials and methods. 
Amplified PCR products were electrophoresed in 1.5% agarose gels and stained with 
ethidium bromide. 
(B). Flow cytometry analysis of CD23 expression. Cell surface expression of mouse 
CD23 in fixed spleen B cells of Wild type or CD23KO mice was measured by flow 
cytometry analysis. CD23 positive B cells, defined as B220+CD23+ cells were analyzed 
by FACS. Spleenocytes (1 x 106) were stained with FITC-conjugated B3B4 and APC-
Cy7 conjugated B220 antibody or its respective isotype control antibodies. The values in 















Mouse CD23 transcytoses IgE in vivo. Human CD23 has been shown to bidirectionally 
transport IgE in the polarized airway epithelial cells (238). To further show IgE 
transcytosis in mouse airway, mouse was inoculated intra-nasally with IgE orPBS (20 
µg/ml).  20 min later, the lung and trachea tissue were sampled for cryosections. The 
interaction between CD23 and IgE was shown by immunohistochemistry staining. As 
shown in  Figure 3.5A, CD23 (red) and mouse IgE (green) were detected and colocalized 
(yellow) in a merged picture. In a PBS control group, we failed to detect such co-
localization. The green color represented mouse IgE was also detected in the lamina 
propria (Figure 3.5A), suggesting an IgE antibody transferring the airway barrier. Similar 
to the tracheal staining CD23 (red) and mouse IgE (green) in the lung tissue were also 
colocalized (yellow) and such colocalization signal was absent in PBS control group 
(Figure 3.5B).  To further show mouse CD23 transcytoses IgE, different amounts of 
mouse IgE were intra-nasally administrated and serum collected at specific time points. 
To mimic the apical to basolateral transcytosis, 20 or 50 µg/ml OVA-specific IgE or PBS 
was applied intra-nasally to wild type and CD23 knockout mice, 4, 8, or 24 hr later, 
serum was collected and tested for appearance of OVA specific IgE by ELISA. When 20 
µg/ml level of IgE was applied intra-nasally, approximately 22 ng/ml and 18 ng/ml 
amount of mouse IgE were detected 4 hr and 8 hr later respectively only in wild type 
mice but not in the CD23 knockout mice.  24 hr later, no IgE was detected in both wild-
type and CD23 knockout mice (Figure 3.5C, top panel). IgE transcytosis in vivo 
exhibited in a dose dependent manner. When 50 µg/ml mouse IgE was applied 
intranasally, there was significantly increased amount of mouse IgE detected in sera of 




significantly higher amount of 90-100 ng/ml mouse IgE was detected in the wild type 
mice compared to 20 ng/ml of mouse IgE in the CD23 knockout mice. However, at 24 hr 
time point, 2 out of 5 mice sera were positive and 3 ng/ml of IgE was detected in wild 
type mice but not in CD23 knockout mice (Figure 3.5C, lower panel). To show whether 
mouse IgE is transcytosed from basolateral to apical direction, 20 or 40 µg/ml mouse 
anti-OVA IgE was injected intra-peritoneally and 8 hr later bronchoalveolar lav ge fluids 
were collected for measuring mouse IgE by ELISA.  When 20 and 40 µg/ml amount of 
mouse IgE were applied intra-peritoneally, significantly increased amount of mouse IgE 
was detected in the BAL in the wild type mice compared to that of CD23 knockout mice 
(Figure 3.5D). PBS was used as a background control in both wild type and CD23 
knockout mice (Figure 3.5C & 3.5D).  
  
CD23 transcytoses IgE derived immune complex across the epithelial barrier. CD23 
and IgE are involved in the enhanced transepithelial antigen transport in intestinal 
epithelial cells of allergic rat and mice (140-142). In previous study, IgE immune 
complex is  found in the BAL fluid of  OVA sensitized and challenged mice and they are 
potent inducers of airway inflammation in comparison with  antigen alone (231).  
However, this study did not show whether CD23 molecule is involved. To prove this, 
mice were intrnasally adminstrated with IgE/OVA immune complex. PBS was used as a 
negative control. To show the co localization of CD23 with IgE and Ova, an 
immunohistochemical staining was performed in lung tissue. The results showed that 
pair-wise co-localization of CD23 (red) with either IgE (green) or ova (green) produces 






















Figure 3.5 Mouse CD23 transcytoses IgE in vivo. 
(A) & (B). Colocalization of CD23 and IgE in naive lung and trachea. Naïve mice were 
anaesthetized with avertin and 20 µg of mouse IgE or PBS was inoculated intranasally. 
Twenty minutes later, the mice were sacrificed and trachea and lung tissue were mounted 
in OCT medium and cryosectioned at 5 µM thickness. The frozen tissue sections were 
fixed and permeabilized with ice-cold acetone and blocked with 10% normal goat serum. 
The sections were incubated with rabbit anti CD23 antibody followed by staining with 
alexa flour 555-conjugated goat anti rabbit antibody and FITC conjugated goat anti 
mouse IgE antibody. The nucleus was stained with DAPI and imaged using LSM510 
confocal microscope. Samples were visualized under same contrast and brightness 
setting.  
(C). Apical to basolateral transcytosis of IgE in naive mice. Wildtype and CD23KO mice 
were inoculated with 50 µg of mouse anti-ova IgE or PBS intranasally. At specified time 
points like 4 hrs, 8 hrs and 24 hrs later, serum was collected from these mice and 
measured for the amount of anti ova IgE transcytosed by ELISA.  
(D). Basolateral to apical transcytosis of IgE in naive mice. Wildtype and CD23KO mice 
were inoculated with 20 µg, 40 µg of mouse anti-ova IgE or PBS intraperitoneally. BAL 
fluid was collected 8 hours later from these mice and measured for the amount of anti ova 















Figure 3.6 CD23 transcytoses IgE derived immune complex across the epithelial 
barrier. 
(A). Colocalization of CD23 and immune complex in naive lung. Immune complex was 
formed with 20 µg anti Ova IgE and 10 µg of ovalbumin at room temperature for 30 
minutes.  Naive mice were anaesthetized with avertin and immune complex or PBS was 
inoculated intranasally. Twenty minutes later, the mice were sacrificed and lung tissue 
was mounted in OCT medium and cryosectioned at 5 µM thickness. The frozen tissue 
sections were fixed and permeabilized with ice-cold acetone and blocked with 10% 
normal goat serum. The sections were incubated with rabbit anti CD23 antibody and 
mouse anti chicken ovalbumin antibody followed by staining with alexa flour 633-
conjugated goat anti rabbit antibody, alexa flour 555-conjugated goat anti mouse 
antibody and FITC conjugated goat anti mouse IgE antibody. The nucleus was stained
with DAPI and imaged using LSM510 confocal microscope. Samples were visualized 
under same contrast and brightness setting.  
(B). Apical to basolateral transcytosis of immune complex in naive lung. Immune 
complex was formed with 20 µg anti Ova IgE and 10 µg of ovalbumin at room 
temperature for 30 minutes.  Naive mice were anaesthetized with avertin and immune 
complex or 10 µg of antigen ovalbumin or PBS was inoculated intranasally. Eight hours 













with Ova (red) produces the yellow (Figure 3.6A). Furthermore, co-localizations of 
mouse CD23 (blue), IgE (green), and OVA (red) were shown in white color (Figure 
3.6A) by analyzing with three color confocal microscopy. As expected, PBS did not give 
any background staining (Figure 3.6A). Immune complex or antigen alone was applied 
intra-nasally, 8 hr later serum was tested for antigen OVA by ELISA. As results shown in 
Figure 3.6B, significant amount of OVA/IgE immune complex was transported in wild 
type mice compared to that of CD23 knockout mice (Figure 3.6B).  However, OVA alone 
were not detected in both wild-type and CD23 knockout mice (Figure 3.6B). Taken 
together, these experiments showed that CD23 is required for specific transport of IgE 
complexed antigen.   
 
Role of CD23 in allergy development. CD23 was shown to be upregualted in allergic 
patients (156, 161). Sensitization of mice also augmented the CD23 expression (Figure 
3.3A & 3.3B). To investigate the role of CD23 in allergy development, wild-type and 
CD23 knockout mice were sensitized and challenged with OVA and BAL fluids were 
collected and analyzed. The level of IL-4 detected in wild type mice was significantly 
higher than that of CD23 KO mice (Figure 3.7A). However, there was no significant 
difference in the level of OVA specific IgE and the number of total leukocytes and 
eosinophils between wild type and CD23 knockout mice (Figure 3.7B & 3.7C). Because 
CD23 is widely expressed in a variety of cells, especially in myeloid cells, the expression 
pattern of CD23 in vivo may influence the experimental results.  
To further show functional difference of CD23 in airway epithelial cells, betwe n 






Figure 3.7 Role of CD23 in allergy development. 
(A)- (C). Detection of IL4, anti-ova IgE, total leukocytes in BAL fluid. Wild type and 
CD23KO mice were sensitized with ova as described in materials and methods. On day 
21, the mice were challenged with 1 % aerosol ova for 30 minutes and 24 hours later 
BAL fluid were collected and measured for IL4 and anti-ova IgE by ELISA. Total 
leukocytes present in the BAL fluid were counted. Cytospin centrifuge the leukocytes, 

















Figure 3.8 Characterization of irradiated CD23 KO mice repopulated with wild-
type bone marrow cells. 
(A)-(B). Flow cytometry analysis of B cells in bone marrow, T cells in spleen. Amount of 
B cells repopulated in bone marrow and T cells in the spleen of irradiated CD23KO mice 
grafted with 5 x 106 wild type bone marrow cells was measured by flow cytometry. 
Normal wild type and CD23KO mice were included as controls. Bone marrow cells or 
spleenocytes (1 x 106) were stained with APC-Cy7 conjugated B220 or PE conjugated 
CD3ε or its isotype controls, AP-Cy7 rat IgG2a or PE hamster IgG1. Results are 
expressed as histograms of fluorescence intensity (log scale). Values in th  top right of 
each rectangle correspond to the proportion of cells stained positive with anti-B220 or 
anti CD3ε antibody relative to the control antibody.  
(C). Flow cytometry analysis of CD23 surface expression in spleen B cells. Cell urface 
expression of mouse CD23 in fixed spleen B cells of irradiated CD23KO mice graftd 
with 5 x 106 wild type bone marrow cells were measured by flow cytometry. Normal wild 
type and CD23KO mice were included as controls. CD23 positive B cells, defined as 
B220+CD23+ cells were analyzed by FACS. Spleenocytes (1 x 106) were stained with 
FITC-conjugated B3B4 and APC-Cy7 conjugated B220 antibody or its respective isotype 
control antibodies. The values in the quadrant represent the percentage of B220+CD 3+ 




chimera wherein, CD23 knockout mice were lethally irradiated and repopulated with 
wild-type bone marrow-derived myeloid cells, so that the chimera are expected to be 
CD23 negative in epithelium but their hematopoietic cells are positive in CD23 
expression. Eight weeks after the irradiated CD23KO mice were  repopulated with wild-
type bone marrow cells, B cells present in spleen were stained positive for CD23 and its 
expression level was similar to that of wild type mice (Figure 3.8C). T cells in spleen and 
B cells in bone marrow (Figure 3.8A & 3.8B) were also detected.  
To demonstrate the role of CD23 expressed exclusively in airway epithelial cells, 
the chimeric mice (WT→CD23KO) along with wild-type mice were sensitized and 
challenged. To maintain the intactness of the airway epithelial barrier, sensitization and 
challenge were performed in a mild condition only for single time.  Although both gr ups 
of mice had equal number of total leukocytes present in the BAL by counting, flow 
cytometry analysis revealed significantly higher amount of approximately 36 % siglec-
F+, 33 % CD11c+ Siglec-F+ macrophages and 4 % CD11c low/- SiglecF+ eosinophils in 
BAL obtained from wild-type mice when compared to the chimeric mice (WT→ 
CD23KO). More importantly, Th2 cytokine IL-4 was also significantly higher in wild-
type mice BAL compared to the chimeric mice (WT→CD23KO). However, there was no 
significant difference between total and OVA specific IgE detected in the BAL fluids 
from both groups of mice. This may be due to the mild sensitization and challenge 
protocol employed to maintain the epithelial barrier. Take together, these experimental 
data suggests that CD23 expressed in the airway epithelium may be involved in the 
development of allergy and contributes to the early stages of allergy development. 






Figure 3.9 CD23 expressed in the respiratory epithelial cells enhances allergy. 
(A)- (D). Wild type and chimeric WT→CD23KO mice were sensitized with 100 mg of 
ova plus 4 mg alum given i/p on day zero. On day 21, the mice were challenged with 1 % 
aerosol ova for 15 minutes and 24 hours later BAL fluids were collected. (A). Total 
leukocytes were counted using hemocytomer. (B)-(C). Flow cytometric analysis of siglec 
F +, CD11c +, CD11c+ SiglecF+ macrophages, CD11clow/- SiglecF+ eosinophils. (D). 












 IgE mediated allergic diseases is more common and increasing in prevalenc in 
developed country (1, 202).  Allergic diseases involve Th2 mediated immune response 
with production of cytokines like IL-4, IL-13, allergen specific IgE, etc. (202, 233). The 
first step in the development of allergic disease is the process of sensitization to a 
particular allergen to elicit Th2 mediated immune response. Subsequent production of 
allergen specific IgE binds to the surface expressed FcεRI on mast cells and basophils. 
The development of allergic inflammations can be divided into two phases. The early 
phase in the development of allergic inflammation involves the inhalation of air borne 
allergen, followed by cross-linking of allergen specific IgE on mast cells and b sophils 
results in degranulation and release of various mediators promoting inflammatory 
reactions (1, 202, 243). The late phase reactions involve synthesis and secretion of 
various cytokines and chemokines which are able to recruit a variety of immune cells 
including leukocytes, eosinophils, monocytes, etc. (1, 202). The airway epithelium acts as 
a major barrier for the inhaled allergen to engage with and activate immune cells in the 
lamina propria. Several mechanisms for airway allergen crossing epithelial barrier have 
been proposed, for example, the intrinsic nature of some allergens having proteolytic 
activity or the luminal allergens sampled by dendritic extensions between the pi lial 
cells from dendritic cells (244). Previously, we have showed that CD23 expressed in th  
human airway epithelial cells acts as a transepithelial transporter for IgE and IgE-derived 
immune complex (238). Here we further demonstrated the expression of CD23 in a 
mouse airway epithelium and it is capable of transporting IgE and IgE based immune 




 Mouse CD23 is expressed in airway epithelial cells isolated from the mice. We 
used various approaches to demonstrate the expression of CD23 at mRNA and protein 
level and immunohistochemistry analysis verified this expression. Similar to human 
CD23 expression pattern in airway epithelial cells (224), mouse lung epithelial cells LA4 
also expressed CD23b but not CD23a mRNA. This result is in agreement with previous 
studies that CD23b is only expressed in mouse intestinal epithelial cells like IEC-4, 
enterocytes isolated from mouse jejunum (142). However, in situ hybridization may be 
useful to further demonstrate the expression patterns of CD23 mRNA in tissue levels of 
mice. Exposure of epithelial cells to Th2 cytokine IL-4 increases the CD23 mRNA 
expression (141, 238). Exposing the murine lung epithelial cell line LA4 to IL-4 also 
augmented the expression of CD23. Most importantly, sensitization of mice with antigen 
OVA significantly enhances CD23 expression in the airway epithelial cells of ung and 
tracheal (Figure 3.3). Immunohistochemistry analysis of mouse lung and trachea furt r 
verified the expression of CD23 protein in the epithelial cells by co-localizing with 
epithelial marker cytokeratin in vivo (Figure 1 & 3). Immunohistochemistry staining 
analysis of CD23 expression was also performed with anti-CD23 mAb B3B4 confirming 
the expression of CD23 in the lung and tracheal epithelial cells (data not shown). These 
data unequivocally suggest CD23 is expressed in mouse airway epithelial cells nd may 
play a role in airway allergic inflammation.  
 CD23 has been shown to have multiple functions, which is involved in IgE-
specific antigen processing and presentation (117-120), homeostasis of IgE (63, 125, 126, 
128), and survival and growth of B cells, T-cells and myeloid precursors (131, 133-135). 




cells in vitro and in mouse intestinal epithelial cells (144, 145, 238). Here, we further 
showed CD23 is capable of transporting IgE across the epithelial barrier in mouse. This 
conclusion is supported by several evidences that CD23 co-localizes with mouse IgE in 
the airway epithelial cells and the sera of wild-type mice have significa t amount of IgE 
after mouse was intranasally inoculated with IgE. There was a time-and dose- ependent 
increases in the amount of IgE transported across the airway epithelium (Figure 3.5). To 
show the specificity of IgE transcytosis by CD23, experiments performed with CD23 KO 
mice demonstrated the limited amount of IgE transported across the epithelial barrier in 
both directions (Figure 3.5). The functional significance of transepithelial transport of 
IgE across the airway epithelial barrier may allow IgE released into the airway lumen, 
subsequently IgE binds to allergen and leads to formation of the immune complex.  
Expression of CD23 allows the immune complex transported back to the lamina propria. 
This CD23-mediated transport mechanism may result in the release of intact allergen 
molecule by the epithelial cell (145), further allowing allergens to interact with immune 
cells underlying epithelial cells.  
 Previous studies have demonstrated that CD23 was capable of delivering the 
intact antigen in the form of IgE immune complex across  human respiratory epithelial 
cells in vitro and in mouse intestinal epithelial cells in vivo (145, 238). Moreover, animal 
sensitization with HRP specifically increases the transepithelial transport of HRP across 
the tracheal epithelium (230) or the intestinal epithelium in the sensitized animals (140-
142). Our data further showed that CD23 is capable of transporting the OVA/IgE immune 
complexes across the airway epithelium from apical to basolateral direction and the intact 




transport mechanism by two ways. First, antigen alone was not transported in either wild 
type or CD23 KO mice and second, CD23 KO mice did not transport OVA/IgE immune 
complex (Figure 3.6).  Moreover, CD23 expressed on B cells is involved in the transport 
of IgE derived immune complex and enhance the antigen presentation (213, 227).  
 The roles of CD23 in airway allergy development remain unknown and 
information in the previous studies is mixed; studies with sensitization and challenge in 
CD23KO mice showed a significant increase in the allergic responses (170, 172, 173) 
and severe impairment of antigen specific IgE mediated immune response (122).  
However, CD23-transgenic mice exhibited suppression in IgE immune response (123). 
Sensitization and challenge with allergen for multiple times may compromise, damage 
and remodel the airway epithelium.  Hence we reduced the sensitization and challenge to 
a single dose. Results from our experiments showed there was no significant difference 
exhibited between wild type and CD23KO mice in the development of allergy (Figure 
3.7). This may be complexed by CD23 expression in a variety of cell types. To exclude 
the role of CD23 expressed in the hematopoietic cells which are important in regulating 
the allergic inflammation, we created chimeric CD23KO mice in which CD23 was not 
expressed in the airway epithelium but were positive in the hematopoietic cells. W  
generated chimeric knock out mice repopulated with wild-type derived bone marrow 
cells, showed the expression of CD23 in the chimeric CD23 KO spleen B cells similar to 
wild-type spleenic B cells, demonstrating that CD23 was negative in epithelial c l s but 
expressed in hematopoietic cells (Figure 3.8). Sensitization and challenge of these mic  
have showed the involvement of CD23 in the early stages of allergy development. 




and IL-4 in the BAL (Figure 3.9), however, we did not find significant difference in total 
and OVA specific IgE in the BAL.  It is possible that a mild sensitization and challenge 
procedure in our study may be a contributing factor. Altogether, we showed that CD23 is 
expressed in the airway epithelium and responsible for the transport of IgE and antigen. 
Expression of CD23 in airway epithelial cells may be responsible in the early stages of 

























Allergic airway inflammations, such as asthma, are an increasingly important 
disease caused by bronchial inflammation and characterized by bronchial hyper-
responsiveness and intermittent airway obstruction with an underlying Th2 cell-biased 
inflammatory response in the airways. Targeting of the functions of Th2 cells and their 
products have been proposed as an effective strategy for the development of potential 
stand-alone treatments for allergic asthma. The reduction or elimination of allergen-
specific Th2 cells in early disease development is expected to reduce the consequences of 
repeated allergic inflammation. Hence, efficient delivery of immunotherapeutic proteins 
into the airway tract could effectively and directly interfere with allergen-specific Th2 
cell activation in its earliest phase of function. However, the polarized epithelial 
monolayer lining the airway forms mucosal barrier which is impervious to 
macromolecule diffusion. This barrier poses a major difficulty for an effici nt delivery of 
immunotherapeutic proteins to access and cross-talk with underlying immune effector 
cells, such as Th2 cells, in the airway. Our recent studies have shown that human CD23 
receptor is functionally capable of transporting IgE antibody across lung and bro chial 
epithelial cells. In this study, we further propose to examine the feasibility of CD23 to 
deliver the immunotherapeutic proteins, CTLA4-Fc (IgE), which are targeted to interfere 




The effect of this fusion protein on the development of allergic inflammation is being
fully investigated in wild-type, CD23-KO, and chimeric mouse model.  
 
INTRODUCTION 
Epithelial monolayers lining the respiratory tracts are impervious to 
macromolecule diffusion in the absence of inflammation, due to the presence of 
intercellular tight junctions at the apical poles. Polarized airway epithelial c lls are 
divided into apical and basolateral domains by tight junctions (148, 149). These domains 
further form mucosal barriers that allow for the selective exchange of macro olecules 
between the lumen and submucosal tissue under physiological conditions. Therefore, 
soluble macromolecules, such as immunotherapeutic proteins, across the mucosal 
epithelium are generally blocked by mucosal barrier. However, crossing of the
macromolecules over the mucosal barrier can be mediated by a transcellular transport 
pathway, or transcytosis. Specifically, the transcellular pathway involves endocytic 
uptake of macromolecules, specifically by receptor-mediated and/or fluid-phase 
endocytosis, at the apical or basolateral membrane (148, 150). The molecules are then 
transported through the cell in endocytic vesicles to the opposite membrane surface, 
where they are released into the lumen or submucosal space. Beneath the epithelial 
lining, lymphocytes, mast cells, basophils, eosinophils, and dendritic cells accumulate in 
either a loosely-infiltrated fashion or an organized fashion forming the organized 
bronchus associated lymphoid tissue (BALT) (1, 148, 149). Therefore, the transcellular 
pathway is a major route in moving soluble macromolecules across the airway epithelial 





 IgE is present in airway secretions; its level can be enhanced in persons who have 
allergic rhinitis or bronchial asthma (1, 206, 207, 234, 236). For many years, the presence 
of IgE in airway secretions has been simply believed to be transduced passively from the 
serum. The complete paucity of mechanistic studies of IgE transport in the airway has 
seriously hampered our understanding of allergic inflammation in the lung. Our recent 
study has found that human and murine respiratory epithelial cells express CD23, a 
receptor for the Fc portion of IgE. In comparison with high affinity IgE receptor FcεRI, 
CD23 was considered as a low affinity receptor for a long time. However, recent studies 
show that CD23 forms a trimer that allows its lectin domains to come within close 
proximity of each other and to cooperate in binding one IgE molecule, consequently 
resulting in CD23’s high affinity binding to IgE antibody (Ka ≈ 10
8 -109 M-1) (1, 63, 64). 
Our recent studies have shown that CD23 is expressed in human airway epithelial cells 
(238). Most importantly, CD23 was functionally capable of transporting IgE antibody 
across human lung and bronchial epithelial cell lines or primary bronchial epithelial cells 
(238). Furthermore, we have demonstrated that mouse IgE was transported across airway 
mucosal barrier in wild-type, but not in CD23 knockout mice, when OVA allergen 
specific IgE molecules were intranasally administrated.  
 
Airway inflammation and dysfunction is one of the most important human 
diseases in the developed world (202). The disease is currently treated with 
bronchodilators or anti-inflammatory drugs such as corticosteroids, leukotriene modifiers, 
and anti-IgE therapy, etc (2). However, the current treatments are not curative and some 
patients do not respond well to intense anti-inflammatory therapies. Additionally, the use 




and more effective intervening strategies are greatly needed and explored.  Airway 
inflammation is characterized by activation of Th2 type CD4+ T cells secreting cytokines 
like IL-4, IL-5, granulocyte-macrophage colony-stimulating factor and eosinophil 
accumulation (233). The Th2 type cells contribute to IgE class switch and development 
of allergen specific IgE secreting plasma cells (236, 237). Thus, inhibiting or eliminating 
Th2 cells is a beneficial strategy for treating asthma as long as a gener lized 
immunosuppression is avoided. Since airway epithelial cells are the first cell layer to 
come into contact with inhaled immunotherapeutic proteins, evidences of CD23-mediated 
IgE transport in polarized airway epithelial cells may lead to the possibility of CD23 
transporting an immune therapeutic proteins, if fused to an IgE Fc fragment, across the 
airway barrier for serving as an immunotherapeutic purpose, consequently modulating or 
dampening the inflammations and hypersensitivity responses in the airway.  
 
Cytotoxic T-lymphocyte antigen 4 (CTLA4) is a homodimer and expressed by 
activated, memory and regulatory T cells (245-248). CTLA4 binds to its ligand CD80 
(also known as B7-1) and CD86 (also known as B7-2) with high affinity on the antigen 
presenting cells (APC) (249-251). Hence, CTLA4 is a negative regulator of T-cell
activation, and its inhibitory effects can be accomplished by competition with CD28 for 
binding to CD80 or CD86 with a much high affinity on APCs, consequently causes 
inhibition of T cell activation and prevents the development of inflammatory diseases 
(252, 253).  Mouse CTLA4-IgG Fc fusion protein immunotherapy inhibits airway 
eosinophilia, reduces airway hyperresponsiveness and prevents mild form of airway 




mouse CTLA4-IgE Fc fusion protein. The impact of the fusion protein transport by CD23 
on airway inflammation and hyper-reactivity was assessed in an ovalbumin (OVA)-based 
murine asthma model. CD23-mediated transport of immunotherapeutic proteins may be 
an important part of intervening strategy for the allergic inflammation. This study may 
offer effective treatment options for patients suffering with allergic diseases, such as 
asthma and chronic obstructive pulmonary disease.  
 
MATERIALS AND METHODS 
Antibodies, cells and reagents. Chinese hamster ovary (CHO) cell line was purchased 
from the American Type Culture Collection (ATCC, Manassas, Virginia). The RBL-2H3 
cell line was a gift from Dr. Juan Rivera (NIH, Bethesda, MD). The CHO-mB7-1 and 
CHO-mB7-2 stable cell lines were obtained from Dr. Gordon Freeman (Harvard Medical 
School, Boston, MA). The cells were cultured in Dulbecco's modified Eagle's medium 
(DMEM) containing 15 % FBS, 1% L-glutamine, non-essential amino acids, 100 U/ml 
penicillin and 100 µg/ml streptomycin. CHO cells harbouring the protein expression 
plasmid was also grown in complete DMEM supplemented with G418 (400 µg/ml). The 
cells were maintained in a humidified atmosphere at 37ºC containing 5% CO2.  Hamster 
anti-mouse CTLA4 mAb, clone UC10-4F10-11, was a kind gift from Dr. Kenneth 
Frauwirth, University of Maryland, College Park, MD and affinity purified mouse anti-
ovalbumin (OVA) IgE was purchased from Bio X-cell (West Lebanon, NH). Rat anti-
mouse IgE mAb, B1E3 was a gift from Dr. Daniel Conrad (Virginia Commonwealth 
University School of Medicine, VA). Proteinase inhibitor cocktail was purchased from 




was obtained from Novus Biologicals (Littleton, CO).  FITC-conjugated goat anti-
hamster IgG was obtained from Rockland (Gilbertsville, PA). HRP conjugated bovine 
anti-goat IgG antibody was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, 
CA).  Biotinylation of mouse anti-OVA IgE antibody was performed with EZ-Link 
Sulfo-NHS-LC-Biotin (Pierce, Rockford, IL) following manufacturer’s in tructions. 
 
Construction, expression, and purification of mouse CTLA4-IgE Fc fusion protein. The 
cDNA encoding the extracellular domain of mouse CTLA4 cDNA was amplified from total 
RNA isolated from mouse spleen using the primer pair (5’-CCGCGGATCCGCGATTTG 
CCCCCCAGCCATGGCTTGTCTTGGACTCCGGAGGTACAAAGC–‘3 & 5’-AGATC 
CCGAGCCACCTCCTCCGGACCCACCCCCGCCTGATCCAGAATCCGGGCATGGTT
C–‘3). The antisense primer encodes a glycine and serine rich linker sequenc s for 14 
codons (GSGGGGSGGGGSGS). The cDNA of mouse IgE Fc fragment coding the CH2, 
CH3 and CH4 domain was amplified from the total RNA extracted from SPE-7 hybridoma 
(kind gift from Zelig Eshhar, Weizmann Institute of Science, Rehovot, Israel) using the 
primer pair (5’- GGATCAGGCGGGGGTGGGTCCGGAGGAGGTGGCTCGGGA 
TCTATCACTGAGCCCACCTTG –‘3 & 5’-ATCTCCGCTCGAGCGGCAGCTACAT 
GGAGGCCTAGGAGGGACGGAGGGAGGTGTT-‘3). Here the forward primer for 
mouse IgE Fc has the complementary sequence for glycine and serine rich linker sequ nce. 
Fusions of mouse CTLA4 and mouse IgE Fc cDNA were performed with PCR-based gene 
assembly method. This fused DNA fragments was ligated into the pCDNA3 vector and the 
sequences were verified by DNA sequencing. The pCDNA3 plasmid containing the mous




colonies were selected and cloned for the secretion of mouse CTLA4-IgE Fc fusion 
proteins. SDS-PAGE and Western blotting, immunofluoresence and ELISA were used to 
verify the expression and secretion of fusion proteins. Cells secreting the highest amount of 
fusion proteins were cloned and purified by affinity chromatography using anti-mouse 
CTLA4 antibody 4F10-Sepharose beads or anti-mouse IgE antibody B1E3-Sepharose 
beads. Either 4F10 or B1E3 mAb was conjugated to the Cyanogen bromide-activated-
Sepharose 4B beads following the manufacturer’s instructions ( Sigma, St. Louis, MO).  
 
SDS-PAGE and Western blotting. SDS-PAGE and Western blot were performed as 
described previously (238). Protein concentrations of cell lysates were determin d by 
Bradford method. The purified proteins or cell lysates were resolved on 12 % SDS-PAGE 
gel electrophoresis under reducing or non-reducing conditions. Proteins were 
electrotransferred onto a nitrocellulose membrane (Schleicher & Schuell) and the 
membrane was blocked with 5% skim milk in PBS. The membrane was probed with goat 
anti-mouse IgE polyclonal antibody for 1 hr at room temperature or overnight at 4°Cnd 
then incubated with HRP-conjugated bovine anti-goat antibody. All blocking, incubation, 
and washing procedures were performed in PBST solution (PBS and 0.05% Tween 20). 
Proteins were visualized using enhanced chemiluminescence (ECL) method (Pierce).  
   
Flow cytometry. Binding of mouse CTLA4-IgE Fc fusion proteins to mouse B7-1 
(CD80), B7-2 (CD86) or FcεRI was analyzed by flow cytometry. For flow staining, 1 X 
106 CHO, CHO-mB7-1, CHO-mB7-2 or RBL-2H3 cells were washed with washing 




Gilbertsville, PA) in PBS on ice for 30 min. The cell suspensions were incubated with 
mouse IgE or purified mouse CTLA4-IgE Fc fusion protein (2 µg/ml) for 30 min at 4°C, 
then washed and further incubated with FITC-conjugated goat anti- mouse IgE Ab 
(1:500)  for 30 min at 4°C. Cells were then washed and analyzed using a FACSAria II 
and the software FlowJo.  
 
Immunocytochemistry. Immunocytochemistry was performed as previously described 
(238). The control CHO and recombinant CHO cells were grown on coverslips to 80% 
confluence overnight. The cells were washed with cold PBS and fixed in 4% 
paraformaldehyde in PBS for 20 min, then washed and quenched with 100 mM glycine 
for 10 min. Then the cells were permeabilized with 0.1% Triton X-100 for 30 min and 
blocked with 3% normal goat serum. After washing, cells were incubated with goat anti-
mouse IgE polyclonal antibody or affinity purified hamster anti-mouse CTLA4, 4F10 
antibody (1 µg/ml) in 3 % normal goat serum in PBS for 1 hr and further incubated with 
FITC-conjugated goat anti-mouse IgE antibody or FITC conjugated goat anti-hamster 
IgG antibody (1:500) for 30 min. After each incubation, cells were washed with PBST
(0.1% Tween 20 in PBS). The prolong antifade reagent (Molecular Probes) was used to 
mount the coverslips and the images were taken using Zesis fluorescent microscope 
(Zeiss Microimaging Inc., NY). Images were processed by Zen 2007 software and Adobe 
Photoshop.   
 
Enzyme-linked immunosorbent assay (ELISA). The mouse CTLA4-IgE Fc fusion 




mouse CTLA4 antibody 4F10 (10 µg/ml) overnight at 4ºC. Plates were then washed three 
times with PBST (0.05% Tween-20 in PBS) and blocked with 10 % FBS in PBS for 1 hr 
at room temperature. Serially two-fold diluted fusion protein or CHO cell culture 
supernatant diluted in 10% FBS in PBS were added and incubated for 2 hr at room 
temperature. Goat anti-mouse IgE (1:1000, Novus Biologicals) and HRP-conjugated 
bovine anti-goat antibody (1:10,000, Santa cruz) were added and further incubated for 1 
hr at room temperature. After each step, plates were completely washed wit  PBST (0.05 
% Tween 20 in PBS). A colorimetric assay was done with substrate tetra methyl 
benzidine (TMB) and hydrogen peroxide and a Victor III microplate reader (Perkin 
Elmer). 
 
 Degranulation assay. Degranulation assay in RBL-2H3 cells was performed as 
previously described with minor modifications (238). The RBL-2H3 (2 X 104/well) cells 
were grown overnight in 96 well plate and sensitized with different concentrations of 
biotinylated IgE (0-500 ng/ml) and mouse CTLA4-IgE Fc fusion protein (0- 2000 ng/ml). 
For measuring spontaneous release, control wells were set without addition of 
biotinylated IgE or fusion protein.  The cells were washed twice with HEPES-Tyrode 
buffer (130 mM NaCl, 5.6 mM glucose, 5 mM KCl, 1.4 mM CaCl2, 1 mM MgCl2, 10 
mM HEPES, 0.1 % BSA, pH 7.4) and samples were collected for measuring the baseline 
degranulation. Degranulation was stimulated by addition of streptavidin (500 ng/ml) in 
HEPES-Tyrode buffer and supernatant collected at 10, 20 and 30 min, followed by 
addition of 0.1 % Triton X-100 and supernatant collected for measuring total enzyme 




marker using 3.3 mM p-nitrophenyl-N-acetyl-β-d-glucosaminide (Sigma-Aldrich) 
dissolved in 0.1 M sodium citrate buffer (pH 4.5) as substrate (50 µl) by incubation at 
37°C for 1 h. The reaction was terminated with a 2 M glycine solution (pH 10.7).  
Quantification of the substrate cleavage was measured by reading absorbance at 405 nM 
and the results were expressed in the percentage of the total cellular concentration.  
 
Statistics. The statistical difference between groups was tested by Student t test. A P 
value of less than .05 was considered significant. Data are expressed as mean ± SD. 
 
RESULTS AND DISCUSSION 
Expression of mouse CTLA4-IgE Fc fusion protein.  Mouse CTLA4 and IgE Fc cDNA 
was amplified, fused with PCR based gene assembly and ligated into pCDNA3 vector 
(Figure 4.1A). The recombinant plasmid was transfected into CHO cells. Fusion protein 
expression was analyzed in a western blot assay (Fig. 4.1B, lane 3). Mouse IgE (Fig. 
4.1B, lane 1) and normal CHO cell lystate (Fig. 4.1B, lane 2) were used as positive r 
negative control. Fusion proteins from the cell culture medium was purified using affiity 
column from Sepharose beads conjugated with either anti-mouse CTLA4, 4F10 mAb or 
anti-mouse IgE, B1E3 mAb. As shown in Figure 4.1C, purified mouse CTLA4-IgE Fc 
fusion protein forms a monomer under reducing condition (Fig. 4.1C, lane 1) and forms a 
dimer under non-reducing conditions (Fig. 4.1C, Lane 2). The predicted molecular 
weight under reducing condition as a monomer is the expected size, however, under non-












Figure 4.1. Construction, purification and expression of mCTLA4-IgE Fc fusion 
protein.  (A) Construction of mCTLA4-IgE Fc plasmid. The mRNA for mCTLA4 (lane 
1) and IgE Fc (lane 2) fused together using PCR based assembly (lane 3) and double 
enzyme digested pCDNA3 plasmid containing mCTLA4-IgE Fc (lane 4).   
(B) Expression in CHO cells. The cell lysates (50 µg) from normal CHO cells (lane 2), 
transfected CHO cell lysates (lane 3) and positive control mouse IgE (lane 1) were gel 
were gel electrophoresed and separated on 12 % SDS-PAGE gel under reducing 
condition. The separated proteins were transferred on nitrocellulose membrane, block d 
and blotted with goat anti mouse IgE antibody. The blots were washed and further 
incubated with HRP conjugated bovine anti goat IgG antibody and the protein bands 
were visualized by ECL method. The arrow indicates the location of mouse IgE and 
mouse IgE Fc. 
(C) Purification of fusion protein. The fusion protein purified using either anti mouse IgE 
B1E3 or anti mouse CTLA4 UC10-4F10-11 conjugated sepharose 4B beads were gel 
were gel electrophoresed and separated on 12 % SDS-PAGE gel under reducing 
condition (lane 1) or under non-reducing condition (lane 2). The separated proteins were 
transferred on nitrocellulose membrane, blocked and blotted with goat anti mouse IgE 
antibody. The blots were washed and further incubated with HRP conjugated bovine anti 
goat IgG antibody and the protein bands were visualized by ECL method. The arrow 
indicates the location of mouse IgE Fc. 
(D) Immunofluorescence detection of fusion protein. The normal or transfected CHO 
cells were grown on glass coverslips, fixed with 4% para-formaldehyde and 
permeabilized in 0.1% Triton X-100. Subsequently, the cells were incubated with goat 
serum for blocking and affinity-purified hamster anti-mouse CTLA4 mAb, followed by 
staining with an FITC conjugated goat Armenian hamster IgG and another set of cells 
were incubated with FITC conjugated anti mouse IgE Ab. The images were 
photographed using Zesis fluorescent microscope. Samples were viewed using the ame 
contrast and brightness settings.  
(E) Detection of fusion protein using ELISA. The purified fusion protein was detected by 













This may be caused by non-reducing conditions in electrophoresis. Immunofluoresence 
staining of transfected CHO cells, but not normal CHO cells, by anti-mouse CTLA4 or 
IgE antibody revealed the expression of the fusion protein (Fig. 4.1D).  In a two-fold 
serial dilution, ELISA detected a decrease in OD450 value for fusion protein but not for 
normal CHO cell culture supernatant (Fig. 4.1E).  
 
Characterization of the CTLA4-Fc fusion protein. Mouse CTLA4 is a negative 
regulator of peripheral T cell immune response by competing with CD28 for binding to 
mouse B7-1 or B7-2. The ability of fusion protein binding to mouse B7-1 or B7-2 
expressed on CHO cells was characterized by flow cytometry. The CTLA4-Fc fusion 
protein alone, but not mouse IgE, bound efficiently to CHO cells expressing B7-1 or B7-
2. The ability for binding to B7-1 CHO cells was much stronger in comparison with that 
of B7-2 CHO cells (Fig. 4.2A). The reduced binding to B7-2 in CHO cells may be due to 
the reduced expression of B7-2 on cell surface or some CHO cells have lost expresion of 
B7-2.  As a negative control, untransfected CHO cells showed a background staining to 
either mouse IgE or to fusion protein (Fig. 4.2A).  
Mouse IgE Fc portion of the CTLA4-Fc fusion protein was characterized by its 
binding ability to FcεRI expressed on RBL-2H3 mast cell line. As shown in Fig. 4.2B, 
fusion protein bound well to FcεRI receptor and 72 % of RBL-2H3 cells stained positive 
while 99 % of the cells stained positive for mouse IgE binding (Fig. 4.2B).   We further 
analyzed whether CTLA4-Fc fusion proteins can block degranulation of RBL-2H3 cells. 
RBL-2H3 cells were incubated overnight with biotinylated IgE antibody together with 




streptavidin for measuring β-Hexosaminidase release. The level of β-Hexosaminidase in 
RBL-2H3 cells that were incubated with biotinylated IgE alone were increased in a time 
dependent manner; interestingly the level of β-Hexosaminidase in the presence of 
CTLA4-Fc fusion proteins was decreased to the background level of mast cells (Fig. 
4.2C). Overall, these data strongly demonstrated that the CTLA4-Fc fusion proteins 
possess their capability to bind to both CD86/CD80 and FcεRI, further suggesting their 
functional integrity.   
 
Future experiments. We will further show whether mouse CD23 can transport CTLA4-
IgE Fc fusion protein across the polarized epithelial cells both in vitro and in vivo. Mouse 
CTLA4-IgE Fc fusion protein will be further tested for their capability to inhibit airway 
eosinophilia and hyperresponsiveness in a murine allergy model. We will intranasally 
administer the affinity purified fusion proteins into the airway tract of wild-type and 
CD23-KO mice and thus analyze its specific transport. The effect of these fusion proteins 
on the development of allergic inflammation will be fully investigated. The impact of 
fusion protein transport on airway inflammation and hyper-reactivity will be ass ssed in 
an ovalbumin (OVA)-based murine asthma model. A chimeric mouse created between 
wild-type and CD23 KO mice will be used to show the specific transport function of 
epithelial CD23 in blocking inflammation initiation and development. The subsequent 
allergic inflammation in the lung will be evaluated by immunological parameters and 











Figure 4.2. Characterization of mCTLA4-IgE Fc fusion protein. 
(A) Fusion protein binding to mouse B7-1 and B7-2. Fusion protein mCTLA4-IgE Fc 
binding affinity to mouse B7-1 and B7-2 expressed on CHO cells was analyzed by flow 
cytometry. Cells were stained as described in Materials and Methods. Results are 
expressed as histograms of fluorescence intensity (log scale). Values in each rectangle 
correspond to the proportion of cells binds to fusion protein. Mouse IgE was used as 
isotype control and binding of fusion protein to normal CHO cells represent the 
background staining.  
(B) Fusion protein binding to RBL-2H3 cells. Fusion protein mCTLA4-IgE Fc binding 
affinity to FcεRI expressed on RBL-2H3 cells was analyzed by flow cytometry. Cells 
were stained as described in Materials and Methods. Results are expressd as histograms 
of fluorescence intensity (log scale). Values in rectangle correspond to the proportion of 
cells binds to fusion protein or positive control mouse IgE. Negative control was 
performed without the addition of any protein.  
(C) Fusion protein blocks degranulation of RBL-2H3 cells. RBL-2H3 cells (2 x 104/well) 
were grown overnight in 48 well plate. Cells were sensitized with biotinylated IgE in the 
presence or absence of fusion protein and degranulated by streptavidin. Degranulation of 
cells was measured by β-Hexosaminidase release in the supernatant and was expressed in 
the percentage of the total cellular concentration. Spontaneous degranulation was 










CHAPTER 5: CONCLUSION AND PRESPECTIVE 
CD23 is a C-type lectin and type II glycoprotein. CD23 has IgE binding activity 
and its expression level is increased in allergies.  CD23 has various functions, such as 
mediating B cell growth, enhancing IgE mediated antigen presentation, and regulating 
IgE homeostasis. In the previous study, CD23 has been shown to transport IgE and IgE-
derived immune complex across the polarized human and mouse intestinal epithelial 
cells. IgE antibody is also present in airway secretions and its level can be increased in 
human patients with allergic rhinitis and bronchial asthma. Little is known about how IgE 
antibodies arrive in the lumen of the respiratory tract. Although CD23 expression was 
previously reported on human enterocytes, it remains unknown in its expression and 
function in airway epithelial cells. In addition, many questions remain to be answered. 
For example, what are the cellular and molecular mechanisms governing CD23-mediated 
IgE transport across the polarized epithelial barrier? How does CD23 release IgE at the 
cell surface following transcytosis? What is the exact role for CD23 in airway 
inflammation? What kind of roles does CD23 function during viral or bacterial infection-
mediated allergic inflammation in the airway? What are all the signals required for CD23 
mediated IgE homeostasis?  
 
In this study, in Chapter 2, I am interested in identifying whether CD23 is 
expressed in the airway epithelium and plays a role in the transport of IgE and immune 
complex. We utilized a variety of approaches to identify that CD23 was expressed in the 
airway epithelial cells like Calu-3 and primary airway epithelial cells. Furthermore, we 




immune complex from the apical to basolateral direction by mimicking in vivo conditi . 
This observation was demonstrated using multiple approaches. First, CD23 was shown to 
be expressed by a variety of human airway epithelial cells like Detroit 562, 16HBE140-, 
Calu-3 and A549 at both mRNA and protein levels. Both immunohistochemistry and 
flow cytometry were used to demonstrate the cellular location of CD23 protein in the 
poliarzed airway epithelial cells. This was also verified in the primary airway epithelial 
cells. Among the two isoforms, CD23b mRNA was found to be expressed at mRNA 
level. Later we also found that CD23 was responsible for transporting IgE bidirectionally 
and IgE derived immune complex from apical to basolateral direction. CD23-mediated 
transcytosis was further confirmed by blocking the transcytosis with either CD23 specific 
antibody or soluble CD23 protein. Furthermore, IL-4 was found to enhance both CD23 
expression as well as CD23 mediated transcytosis of IgE or immune complex across the 
polarized airway epithelial cells. Finally we also found that the transported immune 
complex in comparison with antigen or IgE alone was capable of significantly inducing 
the degranulation in human mast cell line. Taken together, our data demonstrate that 
CD23 is expressed in the airway epithelium responsible for the transport of IgE and 
antigen.  
 
However, several intriguing and important questions remain unanswered. First, 
how does CD23 release transcytosed IgE at the cell surface? Polymeric IgA eceptors 
(pIgR) is responsible for the transport of dimeric IgA from the basolatera to apical 
direction and releases it as secretory component at the apical cell surface by  protein 




responsible for IgG transport and releases IgG by a pH-dependent mechanism (177, 178). 
In our study, CD23 transports IgE bidirectionally and releases IgE at the cell surface. 
However, how CD23 releases its ligand at the cell surface needs to be further tes ed. 
Second, how does CD23 transport IgE and IgE immune complex across the epithelial 
barrier at cellular and molecule level? In our study, we found that the bafilomycin 
inhibiting endosome acidification also reduces IgE transcytosis. Since tubulin is involved 
in the transport of vesicles, IgE bound to CD23 in the vehicles may be transported with 
the help of tubulin. This question needs to be further tested.  Third, how does CD23 
expressed in the airway epithelial cells signal upon binding to IgE or IgE immune 
complex? It has been shown that CD23 expressed in the human intestinal epithelial cells 
activates the MAPK signaling pathway when stimulated with the immune complex.  This 
activation subsequently leads to release of inflammatory mediators like IL-8 and CCL20 
(146, 147).  It will be interesting to know whether CD23 exhibits a similar mechanism or 
stimulate a different signaling pathway in the airway epithelium. The revealing of this 
putative signaling mechanism would be important for understanding IgE-mediated 
allergic inflammation in the airway. Fourth, what is the role of CD23 in allergy and 
asthma development during bacterial or viral infection? We know that bacterial or viral 
infections in the early childhood life influence the development of allergy and asthma in 
the later stages of life (186, 190). It will be interesting to know whether there will be 
correlation between CD23 mediated viral or bacterial specific IgE transport and asthma 
development in an animal model.  
 




epithelial cells was involved in the enhanced transepithelial antigen transport (140-142). 
However, all these studies did not show a direct correlation between the enhanced antigen 
transport and the development of food allergy. In Chapter 3, we found that CD23 was 
expressed in the mouse airway epithelium and transports both IgE and IgE antigen 
immune complex across the epithelial barrier. Sensitization of mice with OVA antigen 
enhanced CD23 expression in the airway epithelium. However, many questions also 
remain to be addressed in this aspect. Although CD23 expressed in the airway epithelium 
of wild type mice may be involved in the early stages of airway allergy developm nt, 
substantial evidences are needed to prove this observation. An IgE-dependent allergy 
model in animals is pivotal to discipher this mechanism.  
 
Previous studies including my work have shown that CD23 was capable of 
transporting IgE across epithelial barrier (140-142, 238). In Chapter 4, I developed and 
characterized IgE based fusion protein made of mouse CTLA4-IgE Fc. However, 
functional characterization of this fusion protein for immunotherapeutic purpose to treat 
allergy remains completely unknown. This fusion protein’s ability to be transported by 
CD23 on the epithelial cells and its immunotherapeutic properties need to be tested very 
carefully.  
 
 In summary, I have demonstrated the expression of CD23 and its function in 
transporting IgE in the airway tract (Fig 5.1). CD23 expressed in the airway t act is 
responsible for the transport of IgE antibody and IgE-allergen immune complexes across 




localized in the lamina propria. Now the immune cells can capture, process and present 
the allergens to naive T cells. In the presence of IL-4, naive T cells differentiate into Th2 
cells. These Th2 cells will secrete cytokines like IL-4, IL-13 and IL-5. Cytokines like IL-
4 and IL-13 allow class switching of B cells to secrete allergen specific IgE antibody. 
Allergens can cross-link the IgE bound to FcεRI expressed at surfaces of mast cells and 
basophils, trig signal cascade, and subsequebtky lead to the release of allergic mediators 
such as histamine, cytokines, chemokines etc. Cytokines like IL-5 can recruit and activate 
eosinophils and all of these finally lead to Th2 mediated allergic inflammation (Fig. 
5.1A). CD23 expressed in the airway epithelium also suggests its potential to deliver IgE-
Fc based fusion protein such as CTLA4-Fc for immunotherapeutic purpose of airway 






















Figure 5.1. Proposed model for CD23 mediated IgE transcytosis and delivery of IgE 
Fc fusion protein for immunotherapy in airway tract. 
(A) CD23 transports IgE and immune complexes. CD23 expressed in the airway 
epithelium was able to transport IgE bidirectionally and IgE allergen complex across the 
airway barrier and deliver intact allergen to the lamina propria, where it can be processed 
and presented by antigen presenting cells to T cells leading to Th2 mediated immune 
response. 
(B) CD23 transports IgE Fc fusion protein. CD23 expressed in airway epithelium 
suggests its ability to deliver IgE Fc fusion protein across the airway epithelium for 
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